

| | | | |
|--|---|---|--|
| FORM PTO-1390 (Modified) (REV 10-95) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTORNEY'S DOCKET NUMBER BB-1332 | |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR) 09/914098 | |
| INTERNATIONAL APPLICATION NO. PCT/US00/04526 | INTERNATIONAL FILING DATE 22 FEBRUARY 2000 (22.02.00) | PRIORITY DATE CLAIMED 22 FEBRUARY 1999 (22.02.99) | |
| TITLE OF INVENTION LYSOPHOSPHATIDIC ACID ACETYLTRANSFERASES | | | |
| APPLICANT(S) FOR DO/EO/US CAHOON, Edgar B. et al. | | | |
| <p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information</p> | | | |
| <p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to being national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application was filed (35 U.S.C. 371 (c) (2))</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p><input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c) (2)).</p> <p><input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</p> <p><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c) (3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p><input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</p> <p>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409)</p> <p>12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</p> | | | |
| <p>Items 13 to 18 below concern document(s) or information included :</p> | | | |
| <p>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>15. <input checked="" type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.</p> <p>16. <input type="checkbox"/> A substitute specification.</p> <p>17. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>18. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail.</p> <p>19. <input type="checkbox"/> Other items or information:</p> | | | |
| <p>17. General Power of Attorney</p> <p>18. Express Mailing Label No. EJ376014714US</p> | | | |

APPLICATION NO. (IF KNOWN, SEE 37 CFR)
09/914098INTERNATIONAL APPLICATION NO.
PCT/US00/04526ATTORNEY'S DOCKET NUMBER
BB-1332

20. The following fees are submitted

CALCULATIONS PTO USE ONLY**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

| | |
|---|-----------|
| <input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO | \$860.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) | \$690.00 |
| <input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) | \$760.00 |
| <input type="checkbox"/> Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO | \$1000.00 |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4) | \$ 100.00 |

ENTER APPROPRIATE BASIC FEE AMOUNT = **\$860.00**Surcharge of **\$130.00** for furnishing the oath or declaration later than
months from the earliest claimed priority date (37 CFR 1.492 (e)). 20 30 **\$0.00**

| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | |
|--|--------------|---|---------|-----------------|
| Total Claims | 20 - 20 = | 0 x | \$18.00 | \$0.00 |
| Independent Claims | 2 - 3 = | 0 x | \$80.00 | \$0.00 |
| Multiple Dependent Claims (check if applicable) | | <input type="checkbox"/> | | \$0.00 |
| TOTAL OF ABOVE CALCULATIONS | | | | \$0.00 |
| Reduction of ½ for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). | | <input type="checkbox"/> | | \$0.00 |
| SUBTOTAL | | | | \$0.00 |
| Processing Fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). | | <input type="checkbox"/> 20 <input type="checkbox"/> 30 | | \$0.00 |
| TOTAL NATIONAL FEE | | | | \$860.00 |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). | | <input type="checkbox"/> | | \$0.00 |
| TOTAL FEES ENCLOSED | | | | \$860.00 |
| | | Amount to be : refunded | \$ | |
| | | Charged | \$ | |

A check in the amount of _____ to cover the above fees enclosed.

Please charge my Deposit Account No. **04-1928** in the amount of **\$860.00** to cover the above fees.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **04-1928** a duplicate copy of this sheet is enclosed.

NOTE : Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (CFR 1.37(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GOLIAN, Paul D.
E. I. DU PONT DE NEMOURS AND COMPANY
Legal Patent Records Center
1007 Market Street
Wilmington, Delaware 19898
United States of America



SIGNATURE

GOLIAN, PAUL D.

NAME

42,591

REGISTRATION NUMBER

August 22, 2001

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

EDGAR B. CAHOON ET AL.

CASE NO.: BB1332 PCT

APPLICATION NO.: UNKNOWN

GROUP ART UNIT: UNKNOWN

FILED: CONCURRENTLY HEREWITH

EXAMINER: UNKNOWN

FOR: LYSOPHOSPHATIDIC ACID
ACETYLTRANSFERASES

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Before examination of the above-referenced application, please amend the application as follows:

IN THE SPECIFICATION:

Please replace the following paragraphs:

Paragraph starting at page 7, line 18:

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not affect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences, and/or (b) SEQ ID

NOS:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an LPAAT isozyme polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial, or viral) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide in the host cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that does not contain the isolated polynucleotide.

Paragraph starting at page 9, line 32:

“Codon degeneracy” refers to divergence in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

IN THE CLAIMS:

Please cancel claims 1-42.

Please add the following new claims:

- 43. An isolated polynucleotide that encodes an LPAAT isozyme polypeptide having a sequence identity of at least 80% based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.
44. The polynucleotide of Claim 43 wherein the sequence identity is at least 85%.
45. The polynucleotide of Claim 43 wherein the sequence identity is at least 90%.
46. The polynucleotide of Claim 43 wherein the sequence identity is at least 95%.
47. The polynucleotide of Claim 43 wherein the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

48. An isolated complement of the polynucleotide of Claim 43, wherein (a) the complement and the polynucleotide consist of the same number of nucleotides, and (b) the nucleotide sequences of the complement and the polynucleotide have 100% complementarity.

49. An isolated nucleic acid molecule that encodes an LPAAT isozyme polypeptide and remains hybridized with the isolated polynucleotide of Claim 43 under a wash condition of 0.1X SSC, 0.1% SDS, and 65°C.

50. A cell or a virus comprising the polynucleotide of Claim 43.

51. The cell of Claim 28, wherein the cell is selected from the group consisting of a yeast cell, a bacterial cell, an insect cell, and a plant cell.

52. A transgenic plant comprising the polynucleotide of Claim 43.

53. A method for transforming a cell comprising introducing into a cell the polynucleotide of Claim 43.

54. A method for producing a transgenic plant comprising (a) transforming a plant cell with the polynucleotide of Claim 43, and (b) regenerating a plant from the transformed plant cell.

55. An isolated LPAAT isozyme polypeptide having a sequence identity of at least 80% based on the Clustal method compared to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

56. The isolated polypeptide of Claim 55 wherein the sequence identity is at least 85%.

57. The isolated polypeptide of Claim 55 wherein the sequence identity is at least 90%.

58. The isolated polypeptide of Claim 55 wherein the sequence identity is at least 95%.

59. The isolated polypeptide of Claim 55 wherein the polypeptide has a sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

60. A chimeric gene comprising the polynucleotide of Claim 43 operably linked to at least one suitable regulatory sequence.

61. The chimeric gene of Claim 60, wherein the chimeric gene is an expression vector.

62. A method for altering the level of an LPAAT isozyme polypeptide expression in a host cell, the method comprising:


- (a) Transforming a host cell with the chimeric gene of claim 60; and
- (b) Growing the transformed cell in step (a) under conditions suitable for the expression of the chimeric gene. --

REMARKS

Applicants respectfully submit that the amendment to the Specification only corrects obvious typographical errors. Furthermore, applicants submit that newly added claims more clearly and distinctly recite that which applicants consider to be their invention, and are adequately supported by the original disclosure.

No new matter is believed to be at issue. Entry of the amendments and early favorable consideration of the claims on the merits are hereby respectfully requested.

Respectfully submitted,



KENING LI
ATTORNEY FOR APPLICANTS
REGISTRATION NO. 44,872
TELEPHONE: (302) 992-3749
FACSIMILE: (302) 892-1026

Dated: 05/24/2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In showing the changes, deleted material is shown as bolded brackets and stricken through, and inserted material is shown underlined.

IN THE SPECIFICATION:

Please replace the following paragraphs:

Paragraph starting at page 7, line 18:

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not affect [effect] the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences, and/or (b) SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an LPAAT isozyme polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial, or viral) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide;

and comparing the level of a polypeptide in the host cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that does not contain the isolated polynucleotide.

Paragraph starting at page 9, line 32:

“Codon degeneracy” refers to divergence in the genetic code permitting variation of the nucleotide sequence without affecting [effecting] the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

CONFIDENTIAL - ATTORNEY-CLIENT

TITLELYSOPHOSPHATIDIC ACID ACETYLTRANSFERASES

This application claims the benefit of U.S. Provisional Application No. 60/121,119, filed February 22, 1999.

5

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology and, in particular, this invention pertains to isolated polynucleotides encoding lysophosphatidic acid acyltransferases in plants and seeds.

BACKGROUND OF THE INVENTION

10 Triacylglycerols are nonpolar, water-insoluble fatty acid triesters of glycerols. Triacylglycerols differ according to the identity and placement of their three fatty acid residues. Lysophosphatidic acid acyltransferase (EC 2.3.1.51), also called 1-acyl-sn-glycerol-3-phosphate acyltransferase, 1-AGP acyltransferase, 1-AGPAT, lysophosphatidic acid transferase, and LPAAT, catalyzes the attachment of the second acyl group to the glycerol backbone during de-novo biosynthesis of triacylglycerols.

15 The fatty acid distribution in triacylglycerols is thought to be dependent on the specificities of the acyltransferases involved in their biosynthesis. Although no plant LPAAT has been purified to completion, spinach leaves have at least two systems which reside in different subcellular compartments (chloroplast inner membrane and the endoplasmic reticulum) and which incorporate different fatty acids into the glycerol backbone (Frentzen et al. (1984) in *Structure, function and metabolism of plant lipids*; Siegenthaler and Eichenberger, eds. pp 105-110). Isolation of LPAAT genes from *Limnanthes douglasii* is dependent on the approach used to isolate the clone. Two different clones have been isolated which varied in their expression patterns, in their ability to complement an *E. coli* temperature-sensitive mutant defective in LPAAT activity and in their ability to hybridize to the already known maize LPAAT (Brown et al. (1995) *Plant Mol. Biol.* 29:267-278). Thus, the presence of many other LPAATs with different specificities, subcellular locations and activities is expected.

20 25 Production of industrially-significant oils in seed oil plants has been a quest of the agricultural industry of some time now. Introduction of the yeast LPAAT sequence into *Arabidopsis* and *B. napus* results in increased seed oil content in many transgenic plants and in changes in seed oil composition (Zou et al. (1997) *Plant Cell* 9:909-923).

SUMMARY OF THE INVENTION

30 35 The invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52, or

(b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

In a second embodiment, it is preferred that the isolated polynucleotide of the claimed invention comprises a first nucleotide sequence which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

In a third embodiment, this invention concerns a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to suitable regulatory sequences.

In a fourth embodiment, this invention concerns an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

In a fifth embodiment, the present invention concerns a process for producing an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention, the process comprising either transforming or transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

In a sixth embodiment, the invention also relates to lysophosphatidic acid acyltransferase (LPAAT isozymes) polypeptides of at least 100 amino acids comprising at least 80% homology based on the Clustal method of alignment compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

In a seventh embodiment, the invention concerns a method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a host cell, preferably a plant cell, the method comprising the steps of: (a) constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level the LPAAT isozyme polypeptide in the host cell containing the isolated polynucleotide; and (d) comparing the level of the LPAAT isozyme polypeptide in the host cell containing the isolated polynucleotide with the level of the LPAAT isozyme polypeptide in the host cell that does not contain the isolated polynucleotide.

In an eighth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of an LPAAT isozyme polypeptide, preferably a plant LPAAT isozyme polypeptide, comprising the steps of: synthesizing an

oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such 5 nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of an LPAAT isozyme amino acid sequence.

In a ninth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding an 10 LPAAT isozyme polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

15 In a tenth embodiment, this invention concerns a composition, such as a hybridization mixture, comprising an isolated polynucleotide of the present invention.

20 In an eleventh embodiment, this invention concerns an isolated polynucleotide of the present invention comprising at least one of 30 contiguous nucleotides derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51.

25 In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette of the present invention; and (b) growing the transformed host cell, preferably plant cell, such as a monocot or a dicot, under conditions which allow expression of the LPAAT isozyme polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

30 In a thirteenth embodiment, this invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58 or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence. All of the 35 embodiments described above are applicable with the exception of the particular sequences involved and the sequence identity being at least 95% as noted in the appropriate claims.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

The invention can be more fully understood from the following detailed description and the accompanying Sequence Listing which form a part of this application.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1
Lysophosphatidic Acid Acyltransferases

| Protein | Clone Designation | SEQ ID NO: (Nucleotide) | SEQ ID NO: (Amino Acid) |
|--|---|----------------------------|----------------------------|
| Corn Polypeptide Similar to <i>Mus musculus</i> LPAAT | Contig of: p0018.chssd06r p0104.cabbd29r cca.pk0027.c9 p0018.chstw94r p0094.csssl20r | 1 | 2 |
| Soybean Polypeptide Similar to <i>Mus musculus</i> LPAAT | sl2.pk121.a19 | 3 | 4 |
| Wheat Polypeptide Similar to <i>Mus musculus</i> LPAAT | Contig of: wlm1.pk0018.g6 wre1n.pk0040.h11 wre1n.pk0064.g7 | 5 | 6 |
| Corn Polypeptide Similar to <i>B. pseudomallei</i> LPAAT | Contig of: ceb5.pk0049.b3 cen3n.pk0027.f6 | 7 | 8 |
| Soybean Polypeptide Similar to <i>B. pseudomallei</i> LPAAT | sgs1c.pk001.i16 | 9 | 10 |
| Wheat Polypeptide Similar to <i>B. pseudomallei</i> LPAAT | wre1n.pk0027.d4 | 11 | 12 |
| Arabidopsis Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein | ads1c.pk005.i10 | 13 | 14 |
| Rice Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein | Contig of: rls6.pk0076.d5 rlr24.pk0068.e3 | 15 | 16 |
| Soybean Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein | scb1c.pk003.d18 | 17 | 18 |
| Rice Polypeptide Similar to Corn LPAAT | Contig of: rr1.pk0004.a10 rr1.pk0039.e10 | 19 | 20 |
| Soybean Polypeptide Similar to Corn LPAAT | Contig of: se4.cp0008.b2 sl2.pk0033.c1 | 21 | 22 |
| Wheat Polypeptide Similar to Corn LPAAT | Contig of: wlk1.pk0004.e7 wle1n.pk0002.g3 | 23 | 24 |

| Protein | Clone Designation | SEQ ID NO: | |
|--|---|--------------|--------------|
| | | (Nucleotide) | (Amino Acid) |
| Catalpa Polypeptide Similar to <i>Mus musculus</i> LPAAT | ncs.pk0013.d2:fis | 25 | 26 |
| Corn Polypeptide Similar to <i>Mus musculus</i> LPAAT | Contig of: ceb1.pk0011.d11 ceb5.pk0053.e3 p0010.cbpqb45r p0018.chssd06r:fis | 27 | 28 |
| Rice Polypeptide Similar to <i>Mus musculus</i> LPAAT | rlr2.pk0028.d6:fis | 29 | 30 |
| Sorghum Polypeptide Similar to <i>Mus musculus</i> LPAAT | gds1c.pk002.a19:fis | 31 | 32 |
| Soybean Polypeptide Similar to <i>Mus musculus</i> LPAAT | sl2.pk121.a19:fis | 33 | 34 |
| Catalpa Polypeptide Similar to <i>B. pseudomallei</i> LPAAT | ncs.pk0009.fl2:fis | 35 | 36 |
| Wheat Polypeptide Similar to <i>B. pseudomallei</i> LPAAT | wre1n.pk0027.d4:fis | 37 | 38 |
| Corn Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein | Contig of: ceb1.mn0001.d12:fis cpe1c.pk006.e1 | 39 | 40 |
| Rice Polypeptide Similar to <i>A. thaliana</i> Protein | rls6.pk0076.d5:fis | 41 | 42 |
| Soybean Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein | scb1c.pk003.d18:fis | 43 | 44 |
| Corn Polypeptide Similar to <i>A. thaliana</i> acyltransferase | ccoln.pk062.p19 | 45 | 46 |
| Rice Polypeptide Similar to <i>A. thaliana</i> acyltransferase | rlr6.pk0094.f6:fis | 47 | 48 |
| Soybean Polypeptide Similar to <i>A. thaliana</i> acyltransferase | sdp4c.pk006.n11:fis | 49 | 50 |
| Soybean Polypeptide Similar to <i>A. thaliana</i> acyltransferase | Contig of: sgs1c.pk005.k7 sgs5c.pk0003.e7 | 51 | 52 |
| Rice Polypeptide Similar to Corn LPAAT | rr1.pk0004.a10:fis | 53 | 54 |
| Soybean Polypeptide Similar to Corn LPAAT | sl2.pk0033.c1:fis | 55 | 56 |
| Wheat Polypeptide Similar to Corn LPAAT | wlk1.pk0004.e7:fis | 57 | 58 |

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB

standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

5

DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide" and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that 10 optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least one of 60 contiguous nucleotides, preferably at least one of 40 contiguous nucleotides, most preferably one of at least 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID 15 NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, or the complement of such sequences and /or (b) SEQ ID NOS:19, 21, 23, 53, 55, and 57 or the complement of such sequences. The term "isolated" polynucleotide is one that has been substantially separated or purified away from other nucleic acid sequences in the cell of the 20 organism in which the nucleic acid naturally occurs, i.e., other chromosomal and extrachromosomal DNA and RNA, by conventional nucleic acid purification methods. The term also embraces recombinant polynucleotides and chemically synthesized 25 polynucleotides.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or 30 more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in 35 one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more

nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences, and/or (b) SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such

nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an LPAAT isozyme polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial, or viral) may 5 comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide in the host 10 cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) Nucleic Acid Hybridisation, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then 15 repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS 20 was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C. 25

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the 30 present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. 35 Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino

acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal 5 method-of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino 10 acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant 15 specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention 20 comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment 25 comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell,

it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic nucleic acid fragments” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art.

5 These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. “Chemically synthesized”, as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis
10 can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.
15

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

35 “Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a

nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise

5 synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various
10 types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

15 The "translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have
20 been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA
30 sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a DNA that is complementary to and derived from a mRNA template using the enzyme reverse transcriptase. The cDNA can be single-stranded or converted into the double
35 stranded form using, for example, the klenow fragment of DNA polymerase I. "Sense" RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the

expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

5 The term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under 10 the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation.

10 The term "recombinant" means, for example, that a recombinant nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by 15 genetic engineering techniques.

15 The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of 20 suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

25 "Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

30 "Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and 35 propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53).

If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and F Levin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).

“PCR” or “polymerase chain reaction” is a technique for the synthesis of large quantities of specific DNA segments. It consists of a series of repetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, CT). Typically, the double-stranded DNA is heat denatured, the two primers complementary to the 3' boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature. One set of these three consecutive steps is referred to as a cycle.

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 10 37, 39, 41, 43, 45, 47, 49, and 51, that codes for the polypeptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

The present invention also concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOS:20, 22, 24, 54, 56, and 58 or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:19, 21, 23, 53, 55 and 57 that codes for the polypeptide selected from the group consisting of SEQ ID NOS:20, 22, 24, 54, 56, and 58.

Nucleic acid fragments encoding at least a portion of several LPAAT isozymes have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other LPAAT isozymes, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling,

nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably one of at least 40, most preferably one of at least 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of:

- (a) SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide, and/or
- (b) SEQ ID NOS:19, 21, 23, 53, 55 and 57 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of an LPAAT isozyme polypeptide preferably a substantial portion of a plant LPAAT isozyme polypeptide, comprising the steps of : synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of:

(a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51and the complement of such nucleotide sequences; and/or
(b) SEQ ID NOs:19, 21, 23, 53, 55 and 57 and the complement of such nucleotide sequences,
5 and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of an LPAAT isozyme polypeptide.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing 10 portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

In another embodiment, this invention concerns host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide of the invention as described herein. Examples of host cells which can be used to practice the invention include, but are not limited to, yeast, bacteria, plants, and viruses.

As was noted above, the nucleic acid polynucleotides of the instant invention may be 20 used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of specific triacylglycerols in those cells. For example overexpression of an LPAAT similar to the maize LPAAT, such as those contained in Example 6, will result in higher oil content in the seed, stem and leaf 25 while overexpression of LPAAT similar to *Burkholderia pseudomallei* will result in larger accumulation of oil in seed.

Overexpression of the proteins of the instant invention may be accomplished by first 30 constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the isolated polynucleotide (or chimeric gene) may be 35 constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different

independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by

5 Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by directing the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present.

10 While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of use may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences.

20 Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

25 Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

In another embodiment, the present invention concerns a polypeptide of at least 100 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

In still another embodiment, the present invention also concerns a polypeptide of at least 100 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOS:20, 22, 24, 54, 56, and 58.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded LPAAT isozyme. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 9).

All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers.

Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the

instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth above is incorporated herein by reference in its entirety.

EXAMPLE 1

Composition of cDNA Libraries: Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various *Arabidopsis*, catalpa, corn, rice, sorghum, soybean, and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2
 cDNA Libraries from Arabidopsis, Catalpa, Corn,
 Rice, Sorghum, Soybean, and Wheat

| Library | Tissue | Clone |
|---------|--|---------------------|
| ads1c | <i>Arabidopsis Wassilewskija</i> 6 day old seedlings | ads1c.pk005.i10 |
| cca | Corn Callus Type II Tissue, Undifferentiated, Highly Transformable | cca.pk0027.c9 |
| ccoln | Corn Cob of 67 Day Old Plants Grown in Green House ¹ | ccoln.pk062.p19:fis |
| ceb1 | Corn Embryo 10 to 11 Days After Pollination | ceb1.mn0001.d12:fis |
| ceb1 | Corn Embryo 10 to 11 Days After Pollination | ceb1.pk0011.d11 |
| ceb5 | Corn Embryo 30 Days After Pollination | ceb5.pk0049.b3 |
| ceb5 | Corn Embryo 30 Days After Pollination | ceb5.pk0053.e3 |
| cen3n | Corn Endosperm 20 Days After Pollination ¹ | cen3n.pk0027.f6 |
| cpe1c | Corn pooled BMS treated with chemicals related to phosphatase ² | cpe1c.pk006.e1 |
| gds1c | Sorghum Seed 20 Days After Pollination | gds1c.pk002.a19:fis |
| ncs | <i>Catalpa speciosa</i> Developing Seed | ncs.pk0009.f12:fis |
| ncs | <i>Catalpa speciosa</i> Developing Seed | ncs.pk0013.d2:fis |
| p0010 | Corn Log Phase Suspension Cells Treated With A23187 ³ to Induce Mass Apoptosis | p0010.cbpbq45r |
| p0018 | Corn Seedling After 10 Day Drought, Heat Shocked for 24 Hours, Harvested After Recovery at Normal Growth Conditions for 8 Hours | p0018.chssd06r |
| p0018 | Corn Seedling After 10 Day Drought, Heat Shocked for 24 Hours, Harvested After Recovery at Normal Growth Conditions for 8 Hours | p0018.chstw94r |
| p0094 | Corn Leaf Collars for the Ear Leaf (EL) and the Next Leaf Above and Below the EL ¹ | p0094.cssl20r |
| p0104 | Corn Roots V5 Stage ⁴ , Corn Root Worm Infested ¹ | p0104.cabbd29r |
| rlr2 | Rice Leaf 15 Days After Germination, 2 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant | rlr2.pk0028.d6:fis |
| rlr24 | Rice Leaf 15 Days After Germination, 24 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant | rlr24.pk0068.e3 |
| rlr6 | Rice Leaf 15 Days After Germination, 6 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant | rlr6.pk0094.f6:fis |
| rls6 | Rice Leaf 15 Days After Germination, 6 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-67 (AVR2-YAMO); Susceptible | rls6.pk0076.d5 |
| rr1 | Rice Root of Two Week Old Developing Seedling | rr1.pk0004.a10 |

| Library | Tissue | Clone |
|---------|---|---------------------|
| rr1 | Rice Root of Two Week Old Developing Seedling | rr1.pk0039.e10 |
| scb1c | Soybean Embryogenic Suspension Culture Subjected to 4 Bombardments and Collected 12 Hours Later | scb1c.pk003.d18 |
| sdp4c | Soybean Developing Pods (10-12 mm) | sdp4c.pk006.n11:fis |
| se4 | Soybean Embryo, 19 Days After Flowering | se4.cp0008.b2 |
| sgs1c | Soybean Seeds 4 Hours After Germination | sgs1c.pk001.i16 |
| sgs1c | Soybean Seeds 4 Hours After Germination | sgs1c.pk005.k7 |
| sgs5c | Soybean Seeds 4 Days After Germination | sgs5c.pk0003.e7 |
| sl2 | Soybean Two-Week-Old Developing Seedlings Treated With 2.5 ppm chlorimuron | sl2.pk0033.c1 |
| sl2 | Soybean Two-Week-Old Developing Seedlings Treated With 2.5 ppm chlorimuron | sl2.pk121.a19 |
| wle1n | Wheat Leaf From 7 Day Old Etiolated Seedling ¹ | wle1n.pk0002.g3 |
| wlk1 | Wheat Seedlings 1 Hour After Treatment With Herbicide ⁵ | wlk1.pk0004.e7 |
| wlm1 | Wheat Seedlings 1 Hour After Inoculation With <i>Erysiphe graminis f. sp tritici</i> | wlm1.pk0018.g6 |
| wre1n | Wheat Root From 7 Day Old Etiolated Seedling ¹ | wre1n.pk0027.d4 |
| wre1n | Wheat Root From 7 Day Old Etiolated Seedling ¹ | wre1n.pk0040.h11 |
| wre1n | Wheat Root From 7 Day Old Etiolated Seedling ¹ | wre1n.pk0064.g7 |

¹These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, the disclosure of which is hereby incorporated by reference.

²Chemicals used included okadaic acid, cyclosporin A, calyculin A, cypermethrin.

³A23187 is commercially available from several vendors including Calbiochem.

⁴Corn developmental stages are explained in the publication "How a corn plant develops" from the Iowa State University Coop. Ext. Service Special Report No. 48 reprinted June 1993.

⁵Application of 6-iodo-2-propoxy-3-propyl-4(3H)-quinazolinone; synthesis and methods of using this compound are described in USSN 08/545,827, the disclosure of which is hereby incorporated by reference.

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid

vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer 5 sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

EXAMPLE 2

Identification of cDNA Clones

10 cDNA clones encoding LPAAT isozymes were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major 15 release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly 20 available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. 25 Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

EXAMPLE 3

Characterization of cDNA Clones Encoding Proteins

Similar to *Mus musculus* LPAAT

30 The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the proteins encoded by the cDNAs to an unknown protein from *Caenorhabditis elegans* and a putative LPAAT protein from *Mus musculus* (NCBI General Identifier Nos. 3878960 and 2317725, respectively). Shown in Table 3 are the BLAST results for individual ESTs ("EST") or for the sequences of contigs assembled from two or 35 more ESTs ("Contig"):

TABLE 3
 BLAST Results for Sequences Encoding Polypeptides
 Homologous to *Mus musculus* LPAAT

| Clone | Status | BLAST pLog Score | |
|------------------|--------|------------------|---------|
| | | 3878960 | 2317725 |
| Contig of: | Contig | 59.40 | 57.70 |
| p0018.chssd06r | | | |
| p0104.cabbd29r | | | |
| cca.pk0027.c9 | | | |
| p0018.chstw94r | | | |
| p0094.csssl20r | | | |
| sl2.pk121.a19 | EST | 15.22 | 10.09 |
| Contig of: | Contig | 54.30 | 50.52 |
| wlm1.pk0018.g6 | | | |
| wre1n.pk0040.h11 | | | |
| wre1n.pk0064.g7 | | | |

5 The sequence of the entire cDNA insert in clones p0018.chssd06r and sl2.pk121.a19 was determined. Further sequencing and analysis of the DuPont proprietary EST database allowed the identification of catalpa, rice, and sorghum clones encoding polypeptides with similarities to *Mus musculus* LPAAT. The BLAST search using the sequences from clones listed in Table 4 revealed similarity of the proteins encoded by the cDNAs to an unknown protein from *Caenorhabditis elegans* and a putative LPAAT protein from *Mus musculus* (NCBI General Identifier Nos. 3878960 and 2317725, respectively). Shown in Table 4 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of the entire protein encoded by a contig assembled from an FIS and one or more ESTs ("Contig*"), or the sequences of the entire protein encoded by an FIS ("CGS").

TABLE 4
 BLAST Results for Sequences Encoding Polypeptides
 Homologous to *Mus musculus* LPAAT

| Clone | Status | BLAST pLog Score | |
|---------------------|---------|------------------|---------|
| | | 3878960 | 2317725 |
| ncs.pk0013.d2:fis | CGS | 56.40 | 54.15 |
| Contig of: | Contig* | 58.00 | 55.04 |
| ceb1.pk0011.d11 | | | |
| ceb5.pk0053.e3 | | | |
| p0010.cbpbq45r | | | |
| p0018.chssd06r:fis | | | |
| rlr2.pk0028.d6:fis | CGS | 57.70 | 55.40 |
| gds1c.pk002.a19:fis | FIS | 58.10 | 45.52 |
| sl2.pk121.a19:fis | CGS | 57.70 | 53.00 |

In this type of plant LPAAT domain I consists of amino acids Asn-His-Thr-Ser-Met-Ile-Asp-Phe-Ile and domain II (62 amino acids downstream) consists of amino acids Leu-Ile-Phe-Pro-Glu-Gly-Thr-Cys.

The data in Table 5 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:2, 4 6, 26, 28, 30, 32, and 34 and the *Caenorhabditis elegans* and *Mus musculus* sequences (NCBI General Identifier Nos. 3878960 and 2317725, respectively).

TABLE 5

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Mus musculus* LPAAT

| SEQ ID NO. | Percent Identity to | |
|------------|---------------------|---------|
| | 3878960 | 2317725 |
| 2 | 38.5 | 35.1 |
| 4 | 39.3 | 29.9 |
| 6 | 39.8 | 35.9 |
| 26 | 31.8 | 35.4 |
| 28 | 32.1 | 36.1 |
| 30 | 31.9 | 37.4 |
| 32 | 33.5 | 36.1 |
| 34 | 32.2 | 35.4 |

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a corn, a sorghum, a soybean and a wheat LPAAT and entire catalpa, corn, rice, and soybean LPAAT proteins. These sequences represent the first catalpa, corn, rice, soybean, and wheat sequences encoding LPAAT proteins of this type.

EXAMPLE 4

Characterization of cDNA Clones Encoding LPAATs Similar to *Burkholderia pseudomallei* LPAAT

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to LPAAT from *Burkholderia*

pseudomallei (NCBI General Identifier No. 3135672). Shown in Table 6 are the BLAST results for individual ESTs ("EST") the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or for the sequences of contigs assembled from two or more ESTs ("Contig"):

5

TABLE 6
BLAST Results for Sequences Encoding Polypeptides Homologous
to *Burkholderia pseudomallei* LPAAT

| Clone | Status | BLAST pLog Score 3135672 |
|---|--------|-----------------------------|
| Contig of: ceb5.pk0049.b3 cen3n.pk0027.f6 | Contig | 9.52 |
| sgs1c.pk001.i16 | FIS | 9.30 |
| wre1n.pk0027.d4 | EST | 4.00 |

10 The sequence of the entire cDNA insert from clone wre1n.pk0027.d4 was determined. Further sequencing and analysis of the DuPont proprietary database allowed the identification of a catalpa clone with similarity to the *Burkholderia pseudomallei* LPAAT. The BLAST search using the sequences from clones listed in Table 7 revealed similarity of the polypeptides encoded by the *Arabidopsis thaliana* contig to similar to acyltransferase 15 (NCBI General Identifier No. 6503307) and of the cDNAs to LPAAT from *Burkholderia pseudomallei* (NCBI General Identifier No. 3135672). Shown in Table 7 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones encoding the entire protein ("CGS"):

20

TABLE 7
BLAST Results for Sequences Encoding Polypeptides Homologous
to *Burkholderia pseudomallei* LPAAT

| Clone | Status | BLAST pLog Score 6503307 | BLAST pLog Score 3135672 |
|---------------------|--------|-----------------------------|-----------------------------|
| ncs.pk0009.f12:fis | CGS | 87.00 | 10.22 |
| wre1n.pk0027.d4:fis | CGS | 83.52 | 11.40 |

25 In this type of plant LPAAT domain I consists of amino acids Asn-His-(Val or Ile)-Ser-Tyr-(Val, Ile, or Leu)-Asp-Ile-Leu and domain II (62 amino acids downstream) consists of amino acids Xaa1-(Leu or Ile)-Phe-Pro-Glu-Gly-Thr-Thr, where Xaa1 is Leu, Ile, Met or Tyr.

The data in Table 8 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:8, 10, 12, 36, and 38 and the *Burkholderia pseudomallei* 30 sequence (NCBI General Identifier No. 3135672).

TABLE 8

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Burkholderia pseudomallei* LPAAT

| SEQ ID NO. | Percent Identity to 3135672 |
|------------|--------------------------------|
| 8 | 19.8 |
| 10 | 17.6 |
| 12 | 17.4 |
| 36 | 219.1 |
| 38 | 20.3 |

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a wheat LPAAT and entire corn, catalpa, soybean, and wheat LPAAT proteins. These sequences represent the first corn, catalpa, soybean, and wheat sequences encoding LPAATs of this type.

EXAMPLE 5

Characterization of cDNA Clones Encoding Putative LPAATs

The BLASTX search using the EST sequences from clones listed in Table 9 revealed similarity of the polypeptides encoded by the contig to an unknown protein from *Arabidopsis thaliana* (NCBI General Identifier No. 2979560). Shown in Table 9 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or the sequences of contigs assembled from two or more ESTs ("Contig"):

TABLE 9
**BLAST Results for Sequences Encoding Polypeptides
 Homologous to LPAATs**

| Clone | Status | BLAST pLog Score |
|---|--------|------------------|
| | | 2979560 |
| ads1c.pk005.i10 | FIS | 52.00 |
| Contig of: rls6.pk0076.d5 rlr24.pk0068.e3 | Contig | 22.70 |
| scb1c.pk003.d18 | EST | 45.04 |

5 The sequence of the entire cDNA insert in clones rls6.pk0076.d5 and scb1c.pk003.d18 was determined. Further sequencing and analysis of the DuPont proprietary database allowed the identification of corn clones with similarities to the *Arabidopsis thaliana* putative protein. The BLAST search using the sequences from clones listed in Table 10 revealed similarity of the polypeptides encoded by the contig to an unknown protein from *Arabidopsis thaliana* (NCBI General Identifier No. 2979560). Shown in Table 10 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones (“FIS”), the sequences of contigs assembled from two or more ESTs (“Contig”), or the sequences of an FIS encoding the entire protein (“CGS”):

TABLE 10
**BLAST Results for Sequences Encoding Polypeptides
 Homologous to LPAATs**

| Clone | Status | BLAST pLog Score |
|---|--------|------------------|
| | | 2979560 |
| Contig of: ceb1.mn0001.d12:fis cpe1c.pk006.e1 | Contig | 21.70 |
| rls6.pk0076.d5:fis | FIS | 67.52 |
| scb1c.pk003.d18:fis | CGS | 81.00 |

15 In this type of plant LPAATs domain I includes the amino acids Ser-Asn-His-(Val or Ile)-Ser-Tyr-Ile-Glu-Pro-Ile and domain II (61 amino acids downstream) includes the amino acids Leu-Leu-Phe-Pro-Glu-Gly-Thr-Thr-Thr.

20 The BLAST search using the sequences from clones listed in Table 11 revealed similarity of the polypeptides encoded by the contig to a member of the acyltransferase family from *Arabidopsis thaliana* (NCBI General Identifier No. 6503307). Shown in Table 11 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones (“FIS”), the sequences of contigs assembled from two or more ESTs (“Contig”), or the sequences of the entire protein encoded by an FIS (“CGS”):

TABLE 11
**BLAST Results for Sequences Encoding Polypeptides
 Homologous to LPAATs**

| Clone | Status | BLAST pLog Score 6503307 |
|---------------------|--------|-----------------------------|
| ccoln.pk062.p19:fis | CGS | 119.00 |
| rlr6.pk0094.f6:fis | CGS | 111.00 |
| sdp4c.pk006.n11:fis | FIS | 95.52 |
| Contig of: | Contig | 6.52 |
| sgs1c.pk005.k7 | | |
| sgs5c.pk0003.e7 | | |

5

In this type of plant LPAATs domain I includes the amino acids Ser-Asn-His-Val-Ser-Tyr-(Val or Leu)-Asp-Ile-Leu and domain II (61 amino acids downstream) includes the amino acids Leu-Phe-Pro-Glu-Gly-Thr-Thr-Thr.

The data in Table 12 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:14, 16, 18, 40, 42, 44, 46, 48, 50, and 52 and the

Arabidopsis thaliana sequences (NCBI General Identifier No. 6503307).

TABLE 12
**Percent Identity of Amino Acid Sequences Deduced From the Nucleotide
 Sequences of cDNA Clones Encoding Polypeptides
 Homologous to LPAATs**

| SEQ ID NO. | Percent Identity to | |
|------------|---------------------|---------|
| | 2979560 | 6503307 |
| 14 | 36.3 | 13.2 |
| 16 | 32.8 | 13.8 |
| 18 | 65.4 | 16.8 |
| 40 | 27.0 | 21.1 |
| 42 | 50.2 | 16.9 |
| 44 | 65.4 | 19.7 |
| 46 | 18.0 | 54.6 |
| 48 | 18.1 | 52.5 |
| 50 | 11.2 | 63.7 |
| 52 | 12.4 | 19.5 |

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.,

20 Madison, WI). Multiple alignment of the sequences was performed using the Clustal

method of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default

parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of an *Arabidopsis*, a corn, a rice, and a soybean LPAAT and an entire soybean LPAAT. These sequences represent the first corn, rice, soybean, and *Arabidopsis* sequences encoding LPAAT of this type.

EXAMPLE 6

Characterization of cDNA Clones Encoding Proteins

Similar to *Zea mays* LPAAT

The BLASTX search using the EST sequences from clones listed in Table 13 revealed similarity of the polypeptides encoded by the cDNAs to LPAAT from *Zea mays* (NCBI General Identifier No. 575960). Shown in Table 13 are the BLAST results for the sequences of contigs assembled from two or more ESTs ("Contig"):

TABLE 13

BLAST Results for Sequences Encoding Polypeptides Homologous to *Zea mays* LPAAT

| Clone | Status | BLAST pLog Score 575960 |
|---|--------|----------------------------|
| Contig of: rr1.pk0004.a10 rr1.pk0039.e10 | Contig | 57.70 |
| Contig of: se4.cp0008.b2 sl2.pk0033.c1 | Contig | 67.15 |
| Contig of: wlk1.pk0004.e7 wle1n.pk0002.g3 | Contig | 78.70 |

The sequence of the entire cDNA insert in clones rr1.pk0004.a10, sl2.pk0033.c1, and wlk1.pk0004.e7 was determined. The BLASTP search using the amino acid sequences from clones listed in Table 14 revealed similarity of the polypeptides encoded by the cDNAs to LPAATs from *Zea mays* and *Brassica napus* (NCBI General Identifier Nos. 1076821 and 4583544, respectively). Shown in Table 14 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones encoding the entire protein ("CGS"):

TABLE 14
 BLAST Results for Sequences Encoding Polypeptides
 Homologous to *Zea mays* LPAAT

| Clone | Status | BLAST pLog Score | |
|--------------------|--------|------------------|---------|
| | | 1076821 | 4583544 |
| rr1.pk0004.a10:fis | CGS | >254.00 | 149.00 |
| sl2.pk0033.c1:fis | CGS | 169.00 | 175.00 |
| wlk1.pk0004.e7:fis | CGS | >254.00 | 148.00 |

5 In this type of plant LPAAT domain I consists of amino acids Ser-Asn-His-Arg-Ser-Asp-Ile-Asp-Trp-Leu and domain II (69 amino acids downstream) consists of amino acids Ala-Leu-Phe-Val-Glu-Gly-Thr-Arg-Phe.

10 The data in Table 15 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOS:20, 22, 24, 54, 56, and 58 and the *Zea mays* sequence (NCBI General Identifier Nos. 1076821).

TABLE 15
 Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Zea mays* LPAAT

| SEQ ID NO. | Percent Identity to 1076821 |
|------------|-----------------------------|
| 20 | 72.6 |
| 22 | 72.4 |
| 24 | 73.1 |
| 54 | 91.2 |
| 56 | 70.1 |
| 58 | 84.8 |

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) CABIOS. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of and an entire rice, soybean, and wheat LPAAT. These sequences represent the first rice, soybean, and wheat sequences encoding LPAATs of this type.

EXAMPLE 7Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below.

5 Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas,

10 15 VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb SalI-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-SalI fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli*

20 25 XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. 30 (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

35 The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236)

which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 µL of ethanol. An aliquot (5 µL) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

EXAMPLE 8Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with fluorescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biostatic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed

expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

5 To 50 μ L of a 60 mg/mL 1 μ m gold particle suspension is added (in order): 5 μ L DNA (1 μ g/ μ L), 20 μ L spermidine (0.1 M), and 50 μ L CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 μ L 70% ethanol and resuspended in 40 μ L of anhydrous ethanol. The DNA/particle suspension can
10 be sonicated three times for one second each. Five μ L of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally
15 bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.
20
25

EXAMPLE 9

Expression of Chimeric Genes in Microbial Cells

30 The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and
35 Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using

oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

Activity assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. For example, assays for LPAAT which incorporates medium-sized chain fatty acids are presented by Knutzon et al. (1995) *Plant Physiol.* 109:999-1006. Assays for LPAAT which incorporates fatty acids longer than 18 carbons are presented by Lassner et al. (1995) *Plant Physiol.* 109:1389-1394. Assays to investigate the fatty acid selectivity of LPAATs is presented by Löhden and Frentzen (1992) *Planta* 188:215-224.

CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
 - 5 (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52, or
10 (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.
 - 15 2. The isolated polynucleotide of Claim 1, wherein the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.
 - 20 3. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are DNA.
 4. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are RNA.
 - 25 5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably linked to suitable regulatory sequences.
 6. An isolated host cell comprising the chimeric gene of Claim 5.
 7. A host cell comprising an isolated polynucleotide of Claim 1.
 - 25 8. The host cell of Claim 7 wherein the host cell is selected from the group consisting of yeast, bacteria, plant, and virus.
 9. The host cell of claim 8 wherein the host cell is a virus.
 - 30 10. A polypeptide of at least 100 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.
 - 35 11. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell, which comprises:
 - (a) constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from an isolated polynucleotide of Claim 1;
 - (b) introducing the isolated polynucleotide into a plant cell;
 - (c) measuring the level of a polypeptide in the plant cell containing the polynucleotide; and

(d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the isolated polynucleotide.

12. The method of Claim 11 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

13. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell which comprises:

- (a) constructing an isolated polynucleotide of Claim 1;
- (b) introducing the isolated polynucleotide into a plant cell;
- (c) measuring the level of polypeptide in the plant cell containing the polynucleotide; and

15 (d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the polynucleotide.

14. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

- (a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences; and
- (b) amplifying a nucleic acid sequence using the oligonucleotide primer.

25 15. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

- (a) probing a cDNA or genomic library with an isolated polynucleotide comprising at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences;
- (b) identifying a DNA clone that hybridizes with the isolated polynucleotide;
- (c) isolating the identified DNA clone; and
- (d) sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

30 16. A composition comprising the isolated polynucleotide of Claim 1.

35 17. A composition comprising the isolated polynucleotide of Claim 10.

18. An isolated polynucleotide comprising the nucleotide sequence having at least one of 30 contiguous nucleotides derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51and the complement of such sequences.

5 19. A method for positive selection of a transformed cell comprising:

(a) transforming a host cell with the chimeric gene of Claim 5; and

(b) growing the transformed host cell under conditions which allow expression of the polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

10 20. The method of Claim 19 wherein the plant cell is a monocot.

21. The method of Claim 19 wherein the plant cell is a dicot.

22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids

15 having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58 or

(b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

23. The isolated polynucleotide of Claim 22, wherein the first nucleotide sequence

20 comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:19, 21, 23, 53, 55 and 57 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

24. The isolated polynucleotide of Claim 22 wherein the nucleotide sequences are DNA.

25 25. The isolated polynucleotide of Claim 22 wherein the nucleotide sequences are RNA.

26. A chimeric gene comprising the isolated polynucleotide of Claim 22 operably linked to suitable regulatory sequences.

27. An isolated host cell comprising the chimeric gene of Claim 26.

30 28. A host cell comprising an isolated polynucleotide of Claim 22.

29. The host cell of Claim 28 wherein the host cell is selected from the group consisting of yeast, bacteria, plant, and virus.

30 30. The host cell of claim 29 wherein the host cell is a virus.

31. A polypeptide of at least 100 amino acids that has at least 95% identity based on 35 the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

32. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell, which comprises:

(a) constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from an isolated polynucleotide of Claim 22;

(b) introducing the isolated polynucleotide into a plant cell;

5 (c) measuring the level of a polypeptide in the plant cell containing the polynucleotide; and

(d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the isolated polynucleotide.

10 33. The method of Claim 32 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID 19, 21, 23, 53, 55 and 57 that codes for the polypeptide selected from the group consisting of SEQ ID NOS:20, 22, 24, 54, 56, and 58.

15 34. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell which comprises:

(a) constructing an isolated polynucleotide of Claim 22;

(b) introducing the isolated polynucleotide into a plant cell;

(c) measuring the level of polypeptide in the plant cell containing the polynucleotide; and

20 (d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the polynucleotide.

35. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

25 (a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOS:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences; and

(b) amplifying a nucleic acid sequence using the oligonucleotide primer.

30 36. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

(a) probing a cDNA or genomic library with an isolated polynucleotide comprising at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOS:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences;

(b) identifying a DNA clone that hybridizes with the isolated polynucleotide;

(c) isolating the identified DNA clone; and

(d) sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

37. A composition comprising the isolated polynucleotide of Claim 22.

38. A composition comprising the isolated polynucleotide of Claim 31.

5 39. An isolated polynucleotide comprising the nucleotide sequence having at least one of 30 contiguous nucleotides derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:19, 21, 23, 53, 55, and 57 and the complement of such sequences.

10 40. A method for positive selection of a transformed cell comprising:

(a) transforming a host cell with the chimeric gene of Claim 26; and

of the polynucleotide in an amount sufficient to complement a null mutant to provide a
positive selection means.

15 41. The method of Claim 40 wherein the plant cell is a monocot.

42. The method of Claim 40 wherein the plant cell is a dicot.

GENERAL POWER OF ATTORNEY
(Concerning Several International Patent Applications)

The undersigned, Vernon R. Rice, Vice President and Assistant General Counsel of E. I. DU PONT DE NEMOURS AND COMPANY, 1007 Market Street, Wilmington, Delaware 19898 USA ("DuPont"), hereby confirms that the power to sign for DuPont has been granted to various individuals (as set forth in the attached excerpt from DuPont's Patent Board Rules of Procedure (January 1988), Appendix Section III.A.4), including the Chairman, Vice-Chairman, and those individuals who are Assistant Secretaries of the Patent Board. Currently these Assistant Secretaries are:

Roger A. Bowman
Linda J. Davis
John E. Griffiths

Barbara J. Massie
Miriam D. Meconnahey
Deborah A. Meginniss

In addition, the authority to act on behalf of DuPont before the competent International Authorities in connection with any and all international patent applications filed by it with the United States as Receiving Office and to make or receive payments on its behalf is hereby granted to:

| | | | |
|------------------------|--------|--------------------------|--------|
| Beardell, Lori Y. | 34,293 | Katz, Elliott A. | 26,396 |
| Belopolsky, Inna | 43,319 | Kelly, Patricia L. | 39,247 |
| Benjamin, Steven C. | 36,087 | King, Karen K. | 34,850 |
| Birch, Linda D. | 38,719 | Kuller, Mark D. | 31,925 |
| Bowen, Jr., Alanson G. | 24,027 | Krukiel, Charles E. | 27,344 |
| Christenbury, Lynne M. | 30,971 | Jarnholm, Arne R. | 30,396 |
| Cotreau, William J. | 36,490 | Langworthy, John A. | 32,255 |
| Deitch, Gerald E. | 30,457 | Lerman, Bart E. | 31,897 |
| Deshmukh, Sudhir | 33,677 | Levitt, Cary A. | 31,848 |
| Dobson, Kevin S. | 40,296 | Magee, Thomas H. | 27,355 |
| Duffy, Roseanne R. | 33,869 | Mayer, Nancy S. | 29,190 |
| Edwards, Mark A. | 39,542 | Medwick, George M. | 27,456 |
| Estrin, Barry | 26,452 | Morrisey, Bruce W. | 30,663 |
| Evans, Craig H. | 31,825 | Reynolds, Stephen E. | 37,580 |
| Fair, Tamera L. | 35,867 | Rizzo, Thomas M. | 41,272 |
| Feltham, S. Neil | 36,506 | Santopietro, Lois A. | 36,264 |
| Floyd, Linda Axamethy | 33,692 | Schaeffer, Andrew L. | 33,605 |
| Fricke, Hilmar L. | 22,384 | Sebree, Chyrrea J. | 45,348 |
| Furr, Robert B. | 32,985 | Shay, Lucas K. | 34,724 |
| Golian, Andrew G. | 25,293 | Shipley, James E. | 32,003 |
| Golian, Paul D. | 42,591 | Siegell, Barbara C. | 30,684 |
| Gorman, Thomas W. | 31,959 | Sinnott, Jessica M. | 34,015 |
| Gould, David J. | 25,338 | Steinberg, Michael A. | 43,160 |
| Griffiths, John E. | 32,647 | Steinberg, Thomas W. | 37,013 |
| Hamby, Jane O. | 32,872 | Stevenson, Robert B. | 26,039 |
| Hamby, William H. | 31,521 | Strickland, Frederick D. | 39,041 |
| Heiser, David E. | 31,366 | Tulloch, Rebecca W. | 36,297 |
| Hendrickson, John S. | 30,847 | Walker, P. Michael | 32,602 |
| Joung, J. Kenneth | 41,881 | Wang, Chen | 38,650 |

The undersigned ratifies fully all actions already taken by the above-named individuals in accordance with the authority granted hereby.

E. I. DU PONT DE NEMOURS AND COMPANY

By:

Vernon R. Rice
Vice President and Assistant General Counsel

O-5-01

DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

LYSOPHOSPHATIDIC ACID ACETYLTRANSFERASES

the specification of which is attached hereto unless the following box is checked:

was filed on **22 February 2000** as U.S. Application No. _____ or PCT International Application No. **PCT/US00/04526** and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

| Application No. | Country | Filing Date | Priority Claimed (Yes/No) |
|-----------------|---------|-------------|---------------------------|
|-----------------|---------|-------------|---------------------------|

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

| U.S. Provisional Application No. | U.S. Filing Date |
|----------------------------------|-------------------------|
| 60/121,119 | 22 FEBRUARY 1999 |

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

| Application No. | Filing Date | Status (patented, pending or abandoned) |
|-----------------|-------------|---|
|-----------------|-------------|---|

POWER OF ATTORNEY: I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

| | |
|--|---|
| Name: LYNNE M. CHRISTENBURY | Registration No.: 30,971 |
| Send correspondence and direct telephone calls to: LYNNE M. CHRISTENBURY | Tel. No. (302) 992-5481 Fax No. (302) 892-7949 |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INVENTOR(S)

| Full Name of Inventor | Last Name CAHOON | First Name EDGAR | Middle Name B. | |
|-------------------------|--|---|---|--------------------------|
| | Signature (please sign full name): <i>Edgar E. Cahoon</i> | | Date: <i>3/31/2000</i> | |
| Residence & Citizenship | City WILMINGTON | State or Foreign Country DELAWARE | Country of Citizenship U.S.A. | |
| Post Office Address | Post Office Address 2331 WEST 18TH STREET | City WILMINGTON | State or Country DELAWARE | Zip Code 19806 |
| Full Name of Inventor | Last Name CAHOON | First Name REBECCA | Middle Name E. | |
| | Signature (please sign full name): <i>Rebecca E. Cahoon</i> | | Date: <i>April 5, 2000</i> | |
| Residence & Citizenship | City WILMINGTON | State or Foreign Country DELAWARE | Country of Citizenship U.S.A. | |
| Post Office Address | Post Office Address 2331 WEST 18TH STREET | City WILMINGTON | State or Country DELAWARE | Zip Code 19806 |
| Full Name of Inventor | Last Name HITZ | First Name WILLIAM | Middle Name D. | |
| | Signature (please sign full name): <i>William D. Hitz</i> | | Date: <i>3/31/2000</i> | |
| Residence & Citizenship | City WILMINGTON | State or Foreign Country DELAWARE | Country of Citizenship U.S.A. | |
| Post Office Address | Post Office Address 404 HILLSIDE ROAD | City WILMINGTON | State or Country DELAWARE | Zip Code 19807 |

Additional Inventors are being named on separately numbered sheets attached hereto.

DECLARATION AND POWER OF ATTORNEY - Page 2

Docket No.: BB1332PCT

| | | | |
|-------------------------|---|--|--|
| Full Name of Inventor | Last Name KINNEY | First Name ANTHONY | Middle Name J. |
| | Signature (please sign full name): <i>Anthony Kinney</i> | | Date: 3/31/2000 |
| Residence & Citizenship | City WILMINGTON | State or Foreign Country DELAWARE DE | Country of Citizenship GB |
| Post Office Address | Post Office Address 609 LORE AVENUE | City WILMINGTON | State or Country Zip Code DELAWARE 19807 |
| Full Name of Inventor | Last Name RIPP | First Name KEVIN | Middle Name G. |
| | Signature (please sign full name): <i>Kevin Ripp</i> | | Date: 3/31/00 |
| Residence & Citizenship | City WILMINGTON | State or Foreign Country DELAWARE DE | Country of Citizenship U.S.A. |
| Post Office Address | Post Office Address 2310 WEST 18TH STREET | City WILMINGTON | State or Country Zip Code DELAWARE 19806 |

SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company
<120> Lysophosphatidic Acid Acetyltransferases
<130> BB1332
<140>
<141>
<150> 60/121,119
<151> 1999-February-22
<160> 58
<170> Microsoft Office 97
<210> 1
<211> 928
<212> DNA
<213> Zea mays

<220>
<221> unsure
<222> (858)

<220>
<221> unsure
<222> (876)

<220>
<221> unsure
<222> (897)

<400> 1
cttttttcc ttcattttcc tattgaaagg gcaagacaag ttggagaagta aaattgagag 60
gaagggtt gaaatgatgt gcagtgttt tggactggat ttatcaagta 120
tcatggacca cggccaaagca cacgacccca tcaggttattc gttgcacaaacc atacatcgat 180
gatagatttc attattctgg agcaaatgac agcatttgct gtcatcatgc agaagcatcc 240
tggatgggtt ggatttattc agaagactat ctggaaagt gtccgttgca tctggttaa 300
tcgtaatgtat ctccgggacc gtgaagttac ggcacggaaat ttacgtgatc atgttcaaca 360
accagacaac aatcctctgt tgattttcc ggaaggaaact tggatgttcaaca accagtacac 420
ggtcatgttc aagaagggtt ccttgagct tggctgcgt gtatgtccaa tagctatcaa 480
gtacaataaa atatttggat atgccttttgc gaacagtaag aagaatattt ttacaatgca 540
cttggtcccg ctgtatgacat catggctgt tggatgttcaaca accagtacac 600
atatctgagg gagggagaga cggcaattgc atttgctgag agagtaaggg acatgatagc 660
tgcttagatgtt gggactaaaga agttcccttgg gatggctatc tggatgttcaaca ccgtccttagt 720
ccccaaacaca ctgaagagaa acaacgcata tttggccaaat ctgtcttgcat gggactggag 780
gagaaatgaa gggacgtaaa gccgtacaag tgcacttcgt tagggttta catgcagcta 840
ccttgttattt ccgttggntt cccaaaaaaa aaaaantgag cctgggacac gtcaaantga 900
ccacctccat ttgggttggta taatttttgc 928

<210> 2
<211> 262
<212> PRT
<213> Zea mays

<400> 2
 Phe Phe Pro Val His Phe Leu Leu Lys Gly Gln Asp Lys Leu Arg Ser
 1 5 10 15
 Lys Ile Glu Arg Lys Leu Val Glu Met Met Cys Ser Val Phe Val Ala
 20 25 30
 Ser Trp Thr Gly Val Ile Lys Tyr His Gly Pro Arg Pro Ser Thr Arg
 35 40 45
 Pro His Gln Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile
 50 55 60
 Ile Leu Glu Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro
 65 70 75 80
 Gly Trp Val Gly Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly Cys
 85 90 95
 Ile Trp Phe Asn Arg Asn Asp Leu Arg Asp Arg Glu Val Thr Ala Arg
 100 105 110
 Lys Leu Arg Asp His Val Gln Gln Pro Asp Asn Asn Pro Leu Leu Ile
 115 120 125
 Phe Pro Glu Gly Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe Lys
 130 135 140
 Lys Gly Ala Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile Lys
 145 150 155 160
 Tyr Asn Lys Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln Ser
 165 170 175
 Phe Thr Met His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val Cys
 180 185 190
 Asp Val Trp Tyr Leu Pro Pro Gln Tyr Leu Arg Glu Gly Glu Thr Ala
 195 200 205
 Ile Ala Phe Ala Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala Gly
 210 215 220
 Leu Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro Ser
 225 230 235 240
 Pro Lys His Thr Glu Glu Lys Gln Arg Ile Phe Ala Glu Ser Val Leu
 245 250 255
 Met Arg Leu Glu Glu Lys
 260

<210> 3
<211> 519
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (46)

<220>
<221> unsure
<222> (69)

<220>
<221> unsure
<222> (72)

<220>
<221> unsure
<222> (86)

<220>
<221> unsure
<222> (117)

<220>
<221> unsure
<222> (142)

<220>
<221> unsure
<222> (144)

<220>
<221> unsure
<222> (186)

<220>
<221> unsure
<222> (241)

<220>
<221> unsure
<222> (245)

<220>
<221> unsure
<222> (347)

<220>
<221> unsure
<222> (368) .. (369)

<220>
<221> unsure
<222> (371)

<220>
<221> unsure
<222> (404)

<220>
<221> unsure
<222> (413)

<220>
<221> unsure
<222> (422)

<220>
<221> unsure
<222> (436)

<220>
<221> unsure
<222> (438)

<220>
<221> unsure
<222> (479)

<220>
<221> unsure
<222> (489)

<220>
<221> unsure
<222> (493)

<220>
<221> unsure
<222> (504)

<220>
<221> unsure
<222> (508)..(509)

<220>
<221> unsure
<222> (516)

<400> 3
gagaactagt ctcgagttt tttttttttt ttttggcat ggaatnattt tcaggcaatt 60
tcatgtana tntacatgta tatcanaata gtaagtggag tacaacaag gggtggngaa 120
aatcattact gaaaaagtaa ananatatac attattttc ctcaaagcgc cgcaacacag 180
actcancgaa tatttggtgc tttccttctc tgtgcttggg actagggcga gaataacttca 240
natancatc ccaaggaacc ttttaagcc cagcacatg ttagattatg tctctaactc 300
tctctgaaa ttcaatgggt gtctctcctg gcttcaaatt ttgtggntcc aagtaccata 360
catcacannc nacagcccaa gatgtcatta attgcaagag atgnctggg aangattgct 420
tncgactatt ccaaancngc atcgacgaaa atttaatgt acttgattgc caccgggnna 480
aaatttgtnc agncaaagtc aaantggnc cttcntgg 519

<210> 4
<211> 107
<212> PRT
<213> Glycine max

<220>
<221> UNSURE
<222> (24)

<220>
<221> UNSURE
<222> (36)

<220>
<221> UNSURE
<222> (43)

<220>
<221> UNSURE
<222> (79)

<220>
<221> UNSURE
<222> (97)

<400> 4

Pro Val Ala Ile Lys Tyr Ile Lys Ile Phe Val Asp Ala Val Trp Asn
1 5 10 15

Ser Arg Lys Gln Ser Phe Thr Xaa His Leu Leu Gln Leu Met Thr Ser
20 25 30

Trp Ala Val Xaa Cys Asp Val Trp Tyr Leu Xaa Pro Gln Asn Leu Lys
35 40 45

Pro Gly Glu Thr Pro Ile Glu Phe Ala Glu Arg Val Arg Asp Ile Ile
50 55 60

Ser His Arg Ala Gly Leu Lys Lys Val Pro Trp Asp Gly Tyr Xaa Lys
65 70 75 80

Tyr Ser Arg Pro Ser Pro Lys His Arg Glu Gly Lys Gln Gln Ile Phe
85 90 95

Xaa Glu Ser Val Leu Arg Arg Phe Glu Glu Lys
100 105

<210> 5
<211> 1067
<212> DNA
<213> Triticum aestivum

<220>
<221> unsure
<222> (935)

<220>
<221> unsure
<222> (1009)

<220>
<221> unsure
<222> (1016)..(1017)

<220>
<221> unsure
<222> (1029)

<220>
<221> unsure
<222> (1034)..(1035)

<220>
<221> unsure
<222> (1061)

<400> 5
tgcttcttgg actggagtga tcaagttacca tggaccacgc ccaagctcac gaccttatca 60
ggattttgtt gcaaaccata catcgatgt agattttatt attctggagc agatgacagc 120
atttgctgtc atcatgcaaa agcatcctgg atgggttggg ttatttcaga agactattct 180
ggaaagtgtg gttgcattcg ggttaaccg taatgatctc aaggatcgtg aagtagttgg 240
aagaaaagtta cgtgatcaag ttccagcatcc agacaacaat cctctcttga ttcccggga 300
aggaacttgt gttataataatc agtacactgt gatgttcaag aagggtgtt ttgagcttgg 360
ctgtgctgtt gttccaaatag ctatcaaata taataaaaata ttgttgcacg cttctggaa 420
tagtaagaag caatcttttta caatgcattt ggttcgtctt atgacatcat gggctgttgt 480
ttgtgatgtt ttgttcttggg aacctcgtt aacccgtt ggttccatggaa gggagacag cgatagaatt 540
tactgaaaga gtgagggaca tgatagctgc tcgggcttggg ctttggaaagg ttccatggaa 600
tggctatctg aaacataacc gcccctagccc caaacatacc gggaaaagg agcgcattt 660
tgctgaatct gtgttgggaa gactagagga aaactaaata gctatcaatc aactcacgg 720
ctccctggta gttgagggtt ttccccttag ttgccttgcata atctgttaat cacccaaatg 780
agacctgggg catgtggaaa tgaccaccgc agttttgtt taaatttttttgcgggttga 840
cagaatcagt agcatgtgtt tggcaagaaa gaactattga atcaaccttg ctatacatac 900
gacactagtc cgatttttgtt acaccacaga tcaancgtt atccctgaac aaactgcagt 960
gaacacagat ttgcgtgtac acaaatttgc acatggatgtt ccataaggntt cgcattnnatg 1020
gatcggttgcna agtnnttaat actaaagatg ttaggttacc naacatt 1067

<210> 6

<211> 231

<212> PRT

<213> Triticum aestivum

<400> 6

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ser | Trp | Thr | Gly | Val | Ile | Lys | Tyr | His | Gly | Pro | Arg | Pro | Ser | Ser |
| 1 | | | | | 5 | | | | | | | | | 10 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Pro | Tyr | Gln | Val | Phe | Val | Ala | Asn | His | Thr | Ser | Met | Ile | Asp | Phe |
| | | | | | 20 | | | | | | | 25 | | | 30 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ile | Leu | Glu | Gln | Met | Thr | Ala | Phe | Ala | Val | Ile | Met | Gln | Lys | His |
| | | | | | 35 | | | | | | | 40 | | | 45 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Gly | Trp | Val | Gly | Phe | Ile | Gln | Lys | Thr | Ile | Leu | Glu | Ser | Val | Val |
| | | | | | 50 | | | | | | | 55 | | | 60 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ser | Gly | Phe | Asn | Arg | Asn | Asp | Leu | Lys | Asp | Arg | Glu | Val | Val | Gly |
| | | | | | 65 | | | | | | | 70 | | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Lys | Leu | Arg | Asp | Gln | Val | Gln | His | Pro | Asp | Asn | Asn | Pro | Leu | Leu |
| | | | | | | 85 | | | | | | | 90 | | 95 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Phe | Pro | Glu | Gly | Thr | Cys | Val | Asn | Asn | Gln | Tyr | Thr | Val | Met | Phe |
| | | | | | 100 | | | | | | | 105 | | 110 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Lys | Gly | Ala | Phe | Glu | Leu | Gly | Cys | Ala | Val | Cys | Pro | Ile | Ala | Ile |
| | | | | | 115 | | | | | | | 120 | | | 125 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Tyr | Asn | Lys | Ile | Phe | Val | Asp | Ala | Phe | Trp | Asn | Ser | Lys | Lys | Gln |
| | | | | | 130 | | | | | | | 135 | | | 140 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Phe | Thr | Met | His | Leu | Val | Arg | Leu | Met | Thr | Ser | Trp | Ala | Val | Val |
| | | | | | 145 | | | | | | | 150 | | | 160 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Asp | Val | Trp | Ser | Trp | Glu | Pro | Gln | Tyr | Leu | Arg | Glu | Gly | Thr | |
| | | | | | | 165 | | | | | | 170 | | | 175 |

Ala Ile Glu Phe Thr Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala
 180 185 190

Gly Leu Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro
 195 200 205

Ser Pro Lys His Thr Glu Glu Lys Gln Arg Met Phe Ala Glu Ser Val
 210 215 220

Leu Arg Arg Leu Glu Glu Asn
 225 230

<210> 7

<211> 1043

<212> DNA

<213> Zea mays

<400> 7

gccccgcgtg cacgctgttc gtggatgcag atggggggcg gccgaggttg gcggggtgga 60
 ggaggaagc cgtgctgcga tcggggtgcgc cgctctcacg ggtgatgctc ttctgtttcg 120
 ggttctactg gatccgcgag acccgccagaa ggtccactaa tgctaagggt ttaaatcagg 180
 accaaattga agaatccaa aggccagggg caattgtatc taatcatgttc tcttatgtgg 240
 atattcttta tcacatgtca gcacatccttc caagtttgt tgctaaggag tcagtgtcca 300
 ggttgccact tattggtctc ataagcaatt gtcttggatg cattttgtt caacgagaat 360
 cgaagtcttc agaagctaaa ggtgtctc tagcgtgtac tggaaaggatc caagacgttt 420
 gtcaagataa gaatacccca atgatgttgt tggttcccga gggaaactact acaaattgggg 480
 attaccttct tccatttaag actggagcct ttcttgcagg tgcaccagtg cagccagtca 540
 ttttggaaata cccttacagg agattttagtc cagcatggg ttcaatggat ggagcacgtc 600
 atgtgtttt gctgctctgt caatttgtaa atcacatggg ggtggtccgg ttgcctgtat 660
 actatccttc tcaactagaa aaagaagatc ctaagctcta cgcaaataat gtcagaaaaac 720
 taatagcaat ggagggcaat ttagttctt ctaatattgg gctggcagag aagcgcgtgt 780
 accatgcagc actgacttgtt agtagtctac ctggcgctag acatgagaaa gatgattgaa 840
 agacgttgcg tcgcttttc tgtaacagac agccgaggaa cactaaaaaa tgtaactgtg 900
 tgctgtttt tataacctgta atgtggcagt ttatttgtt gaggaggctg ttgagttccc 960
 ttctcatact acattgtaca aaaacaatgt ccaatgtcca ttatagttt atgaggttcg 1020
 tgctccaaaaaaa aaaaaaaaaaaa aaa 1043

<210> 8

<211> 278

<212> PRT

<213> Zea mays

<400> 8

Arg Ala Cys Thr Leu Phe Val Asp Ala Asp Gly Gly Arg Pro Arg Leu
 1 5 10 15

Ala Gly Trp Arg Arg Lys Ala Val Leu Arg Ser Gly Cys Ala Leu Ser
 20 25 30

Arg Val Met Leu Phe Val Phe Gly Phe Tyr Trp Ile Arg Glu Thr Arg
 35 40 45

Arg Arg Ser Thr Asn Ala Lys Gly Leu Asn Gln Asp Gln Phe Glu Glu
 50 55 60

Ser Gln Arg Pro Gly Ala Ile Val Ser Asn His Val Ser Tyr Val Asp
 65 70 75 80

Ile Leu Tyr His Met Ser Ala Ser Phe Pro Ser Phe Val Ala Lys Glu
 85 90 95

Ser Val Ser Arg Leu Pro Leu Ile Gly Leu Ile Ser Asn Cys Leu Gly
 100 105 110

Cys Ile Phe Val Gln Arg Glu Ser Lys Ser Ser Glu Ala Lys Gly Val
 115 120 125

Ser Gly Ala Val Thr Glu Arg Ile Gln Asp Val Cys Gln Asp Lys Asn
 130 135 140

Thr Pro Met Met Leu Leu Phe Pro Glu Gly Thr Thr Thr Asn Gly Asp
 145 150 155 160

Tyr Leu Leu Pro Phe Lys Thr Gly Ala Phe Leu Ala Gly Ala Pro Val
 165 170 175

Gln Pro Val Ile Leu Lys Tyr Pro Tyr Arg Arg Phe Ser Pro Ala Trp
 180 185 190

Asp Ser Met Asp Gly Ala Arg His Val Phe Leu Leu Leu Cys Gln Phe
 195 200 205

Val Asn His Met Glu Val Val Arg Leu Pro Val Tyr Tyr Pro Ser Gln
 210 215 220

Leu Glu Lys Glu Asp Pro Lys Leu Tyr Ala Asn Asn Val Arg Lys Leu
 225 230 235 240

Ile Ala Met Glu Gly Asn Leu Val Leu Ser Asn Ile Gly Leu Ala Glu
 245 250 255

Lys Arg Val Tyr His Ala Ala Leu Thr Gly Ser Ser Leu Pro Gly Ala
 260 265 270

Arg His Glu Lys Asp Asp
 275

<210> 9

<211> 1349

<212> DNA

<213> Glycine max

<400> 9

aagaacctga cccaggatga ggatcgctg agcaactcctc ttcatcgatcc cacaaggatt 60
 gcatatcaa tcaagcatcc tgtttccttat ctctgtctc gcatttccct tccttcttct 120
 tctctctctc tctctaaaac octaattcta tacatggaaag gaaaaatctca aatctaatga 180
 ctaattaaatt aatccatcga tcaagcatgg agtccgaact caaagaccc aattcgaagc 240
 cggcgaacgg caacggcaac agcgttcgcg atgaccgtcc tctgtgaag cggagcctc 300
 cggtctccgc cgacagcattc gcccataatgg agaagaagtt cgccgcttac gtccgcccgc 360
 acgtgtacgg caccatggaa cggccgcgatg tgcctccaa ggagaagctc ttgtctcggt 420
 tcgcgttggt cactcttctc cccattcgag tcgttctcgc cgtcaccata ttgtctttt 480
 attacttaat ttgttaggggt tgcactctc tctctgcgcc cactggcgaa gaggaacagg 540
 aagattacgc tcacatgagt gggtgagga gaaccattat tggatgtgt ggacgcgccc 600
 tctccagact catgttttc attttcggct tttattggat ccccaatcg aactctgcct 660
 ctcaggaaaga caagagtcgg cagccccaaag agttggaggag acctggcgta ataatttcta 720
 atcatgtgtc gtacttggat attttgtatc acatgtcttc ctcattccct agttttgttg 780
 ctaagagatc agtggctaaa cttccgcgtag tcggtctcat cagcaagtgc cttgggttgtg 840
 tctatgttca gcggaaatca aggtcatcag acttcaaggg tggatgtgt gttgtcactg 900
 acagaattcg agaagctcat cagaatgagt ctgctccatt aatgtatgtta tttccagaag 960
 gtacaaccac aaatggagag ttcccttcattcaagac tgggtgtttt ttggcaaagg 1020

caccggtaact tcctgtgata ttacgatatac attaccagag atttagccct gcctgggatt 1080
 ccatatctgg agtgcgcacat gtgatatttc tcctgtgtca gtttgtgaat tatatggagg 1140
 tgatccgat acctgttac catccttcac agcaggagat ggatgatccc aaactatacg 1200
 ctaataatgt tagaagggtt atggctactg aggtaattt gatactttct gatattggc 1260
 tagctgaaaa acgaatatat cacgctgctc tcaatggtaa taatagcctg cctagtgttt 1320
 tgcatcagaa agacgaatga taatttcat 1349

<210> 10
 <211> 377
 <212> PRT
 <213> Glycine max

<400> 10
 Met Glu Ser Glu Leu Lys Asp Leu Asn Ser Lys Pro Pro Asn Gly Asn
 1 5 10 15

Gly Asn Ser Val Arg Asp Asp Arg Pro Leu Leu Lys Pro Glu Pro Pro
 20 25 30

Val Ser Ala Asp Ser Ile Ala Asp Met Glu Lys Lys Phe Ala Ala Tyr
 35 40 45

Val Arg Arg Asp Val Tyr Gly Thr Met Gly Arg Gly Glu Leu Pro Pro
 50 55 60

Lys Glu Lys Leu Leu Leu Gly Phe Ala Leu Val Thr Leu Leu Pro Ile
 65 70 75 80

Arg Val Val Leu Ala Val Thr Ile Leu Leu Phe Tyr Tyr Leu Ile Cys
 85 90 95

Arg Val Cys Thr Leu Phe Ser Ala Pro Thr Gly Glu Glu Gln Glu
 100 105 110

Asp Tyr Ala His Met Ser Gly Trp Arg Arg Thr Ile Ile Val Ser Cys
 115 120 125

Gly Arg Ala Leu Ser Arg Leu Met Leu Phe Ile Phe Gly Phe Tyr Trp
 130 135 140

Ile Pro Glu Ser Asn Ser Ala Ser Gln Glu Asp Lys Ser Arg Gln Pro
 145 150 155 160

Glu Glu Leu Arg Arg Pro Gly Val Ile Ile Ser Asn His Val Ser Tyr
 165 170 175

Leu Asp Ile Leu Tyr His Met Ser Ser Ser Phe Pro Ser Phe Val Ala
 180 185 190

Lys Arg Ser Val Ala Lys Leu Pro Leu Val Gly Leu Ile Ser Lys Cys
 195 200 205

Leu Gly Cys Val Tyr Val Gln Arg Glu Ser Arg Ser Ser Asp Phe Lys
 210 215 220

Gly Val Ser Ala Val Val Thr Asp Arg Ile Arg Glu Ala His Gln Asn
 225 230 235 240

Glu Ser Ala Pro Leu Met Met Leu Phe Pro Glu Gly Thr Thr Asn
 245 250 255

Gly Glu Phe Leu Leu Pro Phe Lys Thr Gly Gly Phe Leu Ala Lys Ala
260 265 270

Pro Val Leu Pro Val Ile Leu Arg Tyr His Tyr Gln Arg Phe Ser Pro
275 280 285

Ala Trp Asp Ser Ile Ser Gly Val Arg His Val Ile Phe Leu Leu Cys
290 295 300

Gln Phe Val Asn Tyr Met Glu Val Ile Arg Leu Pro Val Tyr His Pro
305 310 315 320

Ser Gln Gln Glu Met Asp Asp Pro Lys Leu Tyr Ala Asn Asn Val Arg
325 330 335

Arg Leu Met Ala Thr Glu Gly Asn Leu Ile Leu Ser Asp Ile Gly Leu
340 345 350

Ala Glu Lys Arg Ile Tyr His Ala Ala Leu Asn Gly Asn Asn Ser Leu
355 360 365

Pro Ser Val Leu His Gln Lys Asp Glu
370 375

<210> 11
<211> 585
<212> DNA
<213> Triticum aestivum

<220>
<221> unsure
<222> (363)

<220>
<221> unsure
<222> (391)

<220>
<221> unsure
<222> (404)

<220>
<221> unsure
<222> (433)

<220>
<221> unsure
<222> (439)

<220>
<221> unsure
<222> (449)

<220>
<221> unsure
<222> (470)

<220>
<221> unsure
<222> (510)

<220>
<221> unsure
<222> (527)

<220>
<221> unsure
<222> (532)

<220>
<221> unsure
<222> (535)

<220>
<221> unsure
<222> (539)

<220>
<221> unsure
<222> (557)

<220>
<221> unsure
<222> (562)

<220>
<221> unsure
<222> (571)

<400> 11
caggggttga ggagggaggc cgtgctgcgt gctggccgcg tggcgcg ggcaatgctg 60
ttcgtgttcg ggttctactg gatccccgtg tccgatcgaa gcttccccaa tgccgaggat 120
gtacctaaag atcactatga agaactggaa agaccagggg cgattgtatc taatcatgtg 180
tcatatgtgg acattctta tcataatgtca gcttcttctc cgagttttgt tgctaagaac 240
tcagtgtcca agttgccgtt gattggtctc ataagcaaat gtcttggtt cattttgtt 300
caacgagaac caaatgttca gattctaaag ggtctcaagt gctgttaactg aaagtccatg 360
agntcacaag gacgagaatc cctatatcta nccttcctg aggntacact acaatggat 420
tactctccat tanacaganc ttcttgang gacatgcaac tgtatttgnn atacctacag 480
agattatcca cctgggacca tggatggacn caagtttttg ccccccgnatt tnaantaana 540
agggtccctt ctgaaaanact cncaaaaaga ngttcaatca gcaaa 585

<210> 12
<211> 194
<212> PRT
<213> Triticum aestivum

<220>
<221> UNSURE
<222> (120)

<220>
<221> UNSURE
<222> (130)

<220>
<221> UNSURE
<222> (134)

<220>
<221> UNSURE
<222> (144)

<220>
<221> UNSURE
<222> (146)

<220>
<221> UNSURE
<222> (149)

<220>
<221> UNSURE
<222> (156)

<220>
<221> UNSURE
<222> (175)

<220>
<221> UNSURE
<222> (177) .. (178) .. (179)

<220>
<221> UNSURE
<222> (185)

<220>
<221> UNSURE
<222> (187)

<220>
<221> UNSURE
<222> (190)

<400> 12
Gln Gly Leu Arg Arg Glu Ala Val Leu Arg Ala Gly Arg Val Leu Ser
1 5 10 15

Arg Ala Met Leu Phe Val Phe Gly Phe Tyr Trp Ile Pro Val Ser Asp
20 25 30

Arg Ser Phe Pro Asn Ala Glu Asp Val Pro Lys Asp His Tyr Glu Glu
35 40 45

Leu Glu Arg Pro Gly Ala Ile Val Ser Asn His Val Ser Tyr Val Asp
50 55 60

Ile Leu Tyr His Met Ser Ala Ser Ser Pro Ser Phe Val Ala Lys Asn
65 70 75 80

Ser Val Ser Lys Leu Pro Leu Ile Gly Leu Ile Ser Lys Cys Leu Gly
85 90 95

Cys Ile Phe Val Gln Arg Glu Pro Asn Val Gln Ile Leu Lys Gly Leu
100 105 110

Lys Cys Cys Asn Lys Ser Met Xaa Ser Gln Gly Arg Glu Ser Leu Tyr
 115 120 125

Leu Xaa Phe Pro Glu Xaa Thr Leu Gln Trp Asp Tyr Ser Pro Leu Xaa
 130 135 140

Arg Xaa Ser Cys Xaa Asp Met Gln Leu Tyr Leu Xaa Tyr Leu Gln Arg
 145 150 155 160

Leu Ser Thr Trp Asp His Asp Gly Thr Gln Val Phe Ala Pro Xaa Phe
 165 170 175

Xaa Xaa Xaa Arg Val Pro Ser Glu Xaa Leu Xaa Lys Arg Xaa Ser Ile
 180 185 190

Ser Lys

<210> 13

<211> 1501

<212> DNA

<213> *Arabiaopsis thaliana*

<400> 13

atgcagaatc atgtggatta ctcggatctg taccagatgt atccctttctt cttttggcta 60
 tcagtggata agaaggaaag ggaaacctgc tcggagagag attgctccga ttgttgtatc 120
 aaatcatgtt tcttatattt aaccaatctt ctacttctat gaattatcac cgaccattgt 180
 tgcacatggag tcacatgatt cacttccatt tggttgaact attatcaggg caatgcaggt 240
 gatatatgtt aatagattct cacagacatc aaggaagaat gctgtgcattt aaataaagag 300
 aaaagcttcc tgcgatagat ttccctcgat gctgttattt cccgaaggaa ccacgactaa 360
 tgggaaagtt cttatttcct tccaaactcggt tgctttcatc cctgggttacc ctattcaacc 420
 tggtagtagtc cggtatcccc atgtacattt tgatcaatcc tggggaaata tctctttgtt 480
 gacgctcatg ttttagaatgt tcactcagtt tcacaatttc atggaggttg aatatcttcc 540
 tgtaatctat cccagtgaaa agcaaaagca gaatgctgtt cgtctctcac agaagactag 600
 tcattcaattt gcaacatctt tgaatgtcgat ccaaacatcc cattttttt cgacttgat 660
 gctactcaac aaagcaactg agttaaagct ggagaacccc tcaaattaca tggttggaaat 720
 ggcaagagtt gagtcgttat tccatgttcaag cagcttagag gcaacgcgtt ttttggatac 780
 atttggttcc atgattccgg actcgagtgg acgtgtttagg ctacatgact ttcttcgggg 840
 tcttaaactg aaaccttgcc ctcttctaa aaggatattt gagttcatcg atgtggagaa 900
 ggtcgatca atcaacttca aacagtctt gtttgcctcg gcccacgtgt tgacacagcc 960
 gcttttaag caaacatgcg agcttagcctt ttcccattgc gatgcagatg gagatggcta 1020
 tattacaattt caagaactcg gagaagctt caaaaacaca atcccaaact tgaacaagga 1080
 cgagattcga ggaatgtacc atttgcata cgacgaccaa gatcaaagaa tcagccaaaa 1140
 tgacttgcattt tcctgctttaa gaagaaaccc tcttctcata gccatcttt cacctgactt 1200
 ggcccccaaca taacacagag agacaaaatg gctggcttcaag atttgcgtt cgtatgtt 1260
 aaacttgcattt ttgtggata ttattatacc ttttgcatttgc tcttcatatt tgatttcagc 1320
 tagtaaaaag aagggactgc tatgtttta gcctatataat ataccctcct ccaacatgga 1380
 tccatccttt tgactgttgg actataactg cttgtcgat tccaccccaa aaaacgctat 1440
 ggtgtttgc cctcttagttc tgaccaaact ttgtgtaaa aaaaaaaaaaaa aaaaaaaaaaa 1500
 a 1501

<210> 14

<211> 403

<212> PRT

<213> *Arabidopsis thaliana*

<400> 14

Cys Arg Ile Met Trp Ile Thr Arg Ile Cys Thr Arg Cys Ile Leu Phe
 1 5 10 15

Ser Phe Gly Tyr Gln Trp Ile Arg Arg Lys Gly Lys Pro Ala Arg Arg
 20 25 30

Glu Ile Ala Pro Ile Val Val Ser Asn His Val Ser Tyr Ile Glu Pro
 35 40 45

Ile Phe Tyr Phe Tyr Glu Leu Ser Pro Thr Ile Val Ala Ser Glu Ser
 50 55 60

His Asp Ser Leu Pro Phe Val Gly Thr Ile Arg Ala Met Gln Val
 65 70 75 80

Ile Tyr Val Asn Arg Phe Ser Gln Thr Ser Arg Lys Asn Ala Val His
 85 90 95

Glu Ile Lys Arg Lys Ala Ser Cys Asp Arg Phe Pro Arg Leu Leu Leu
 100 105 110

Phe Pro Glu Gly Thr Thr Asn Gly Lys Val Leu Ile Ser Phe Gln
 115 120 125

Leu Gly Ala Phe Ile Pro Gly Tyr Pro Ile Gln Pro Val Val Val Arg
 130 135 140

Tyr Pro His Val His Phe Asp Gln Ser Trp Gly Asn Ile Ser Leu Leu
 145 150 155 160

Thr Leu Met Phe Arg Met Phe Thr Gln Phe His Asn Phe Met Glu Val
 165 170 175

Glu Tyr Leu Pro Val Ile Tyr Pro Ser Glu Lys Gln Lys Gln Asn Ala
 180 185 190

Val Arg Leu Ser Gln Lys Thr Ser His Ala Ile Ala Thr Ser Leu Asn
 195 200 205

Val Val Gln Thr Ser His Ser Phe Ala Asp Leu Met Leu Leu Asn Lys
 210 215 220

Ala Thr Glu Leu Lys Leu Glu Asn Pro Ser Asn Tyr Met Val Glu Met
 225 230 235 240

Ala Arg Val Glu Ser Leu Phe His Val Ser Ser Leu Glu Ala Thr Arg
 245 250 255

Phe Leu Asp Thr Phe Val Ser Met Ile Pro Asp Ser Ser Gly Arg Val
 260 265 270

Arg Leu His Asp Phe Leu Arg Gly Leu Lys Leu Lys Pro Cys Pro Leu
 275 280 285

Ser Lys Arg Ile Phe Glu Phe Ile Asp Val Glu Lys Val Gly Ser Ile
 290 295 300

Thr Phe Lys Gln Phe Leu Phe Ala Ser Gly His Val Leu Thr Gln Pro
 305 310 315 320

Leu Phe Lys Gln Thr Cys Glu Leu Ala Phe Ser His Cys Asp Ala Asp
 325 330 335

Gly Asp Gly Tyr Ile Thr Ile Gln Glu Leu Gly Glu Ala Leu Lys Asn
 340 345 350

Thr Ile Pro Asn Leu Asn Lys Asp Glu Ile Arg Gly Met Tyr His Leu
 355 360 365

Leu Asp Asp Asp Gln Asp Gln Arg Ile Ser Gln Asn Asp Leu Leu Ser
 370 375 380

Cys Leu Arg Arg Asn Pro Leu Leu Ile Ala Ile Phe Ala Pro Asp Leu
 385 390 395 400

Ala Pro Thr

<210> 15
<211> 692
<212> DNA
<213> Oryza sativa

<220>
<221> unsure
<222> (446)

<220>
<221> unsure
<222> (579)

<220>
<221> unsure
<222> (677)

<400> 15
gttctaacc gcctccatc gcctcgctc cgccacccat ggttctcgaa acccttagcc 60
ccgcctccct ctccacgccc ctccctctccg actccatctc gcccacgccc accaccaacg 120
gccacgcggg gcaccataac cacgacgacg acgacgagga gtgcgccaacg gtgtgcggcg 180
gcgatggcg aggagggggg gacccgttcg cgttccatc ggaggatcg ccggcgttgt 240
ggtcgcccgcg ggggtgtcc cggccgacc cgttccgcaa cgggacgccc ggggtgtgcg 300
ggcgtagcgtacg gctcggtgagg gcgcgtgtgt gcgcgcgggt ggcggcggcg aggctgggtgc 360
tgttcgggtctccatcggtgtgggtacgcg cgcgcacgtgcgtggcgcgtc cgcgggtggg 420
tcgacgtgcg ggagcggggcg gcgcangagg gcgcgcggcc catgcggcg tggcggccgc 480
gcctcatgtg gatcacgcggg attccgcgcgcgtc atccatctc ttctccatcg gatacatgg 540
ataaggagaa aggaaaacccgcctagaaac ttcaactatnt ttctaaatca tgttcatcat 600
agaaccatat actctcatag ctccgcacat cgttctcaaa tccatatcat acattttgaa 660
aatttcagca tcagtantag taaaaatccc aa 692

<210> 16
<211> 174
<212> PRT
<213> Oryza sativa

<220>
<221> UNSURE
<222> (136)

<400> 16
Met Ala Ser Arg Asn Pro Ser Pro Ala Ser Leu Ser Thr Pro Leu Leu
1 5 10 15

Ser Asp Ser Ile Ser Pro Thr Pro Thr Thr Asn Gly His Ala Gly His
 20 25 30

His Asn His Asp Asp Asp Asp Glu Glu Ser Pro Thr Val Cys Gly Gly
 35 40 45

Asp Gly Gly Gly Gly Asp Pro Phe Ala Phe Leu Ser Glu Asp Arg
 — 50 55 60

Pro Ala Trp Trp Ser Pro Arg Gly Val Ser Pro Ala Asp Pro Phe Arg
 65 70 75 80

Asn Gly Thr Pro Gly Trp Cys Gly Ala Tyr Glu Leu Val Arg Ala Leu
 85 90 95

Val Cys Ala Pro Val Ala Ala Arg Leu Val Leu Phe Gly Leu Ser
 100 105 110

Ile Ala Val Gly Tyr Ala Ala Thr Trp Val Ala Leu Arg Gly Trp Val
 115 120 125

Asp Val Arg Glu Arg Ala Ala Xaa Glu Gly Ala Gly Pro Met Pro Ala
 130 135 140

Trp Arg Arg Arg Leu Met Trp Ile Thr Arg Ile Pro Arg Ala Ala Ser
 145 150 155 160

Ser Ser Pro Ser Asp Thr Leu Asp Lys Glu Lys Gly Lys Pro
 165 170

<210> 17
 <211> 480
 <212> DNA
 <213> Glycine max

<220>
 <221> unsure
 <222> (189)

<220>
 <221> unsure
 <222> (195)

<220>
 <221> unsure
 <222> (284)

<220>
 <221> unsure
 <222> (290)

<220>
 <221> unsure
 <222> (303)

<220>
 <221> unsure
 <222> (362)

<220>
<221> unsure
<222> (366)

<220>
<221> unsure
<222> (377) .. (378)

<220>
<221> unsure
<222> (399)

<220>
<221> unsure
<222> (419)

<220>
<221> unsure
<222> (426)

<220>
<221> unsure
<222> (428)

<220>
<221> unsure
<222> (432)

<220>
<221> unsure
<222> (454)

<220>
<221> unsure
<222> (475)

<400> 17
gcgacgacga cgacttctcc gtgccgccac cgtccaccct ggaccggttc cgcaaccgca 60
cgccggcgat cgaggggctc tacaggatggg ccaagacggc gctgtgcctg ccgctggcgg 120
cgctgcggct cgcgctgttc gggctctgcc tcgcgggtgg gtacgtggcg acgaagggtgg 180
cgctggcang gtggnaggac aaggagaatc ccatgccc aa gtggagggtgt agggtttatgt 240
ggatcacgcg ctgtgcgcc aaatgtattc tcttctcctt tggttatcan tggataaaac 300
ggnaaggaa acctgcacca agggaaatt gctccaataa attgtatcta aaccatgttt 360
cntaanagtg agcctannct tcctatitct aagaattant tcctaacaat ggtggaaanc 420
tgaagnncna anactccata tcctttgtt gggnaccaat taatagagca aatgnaagtc 480

<210> 18
<211> 107
<212> PRT
<213> Glycine max

<220>
<221> UNSURE
<222> (63)

<220>
<221> UNSURE
<222> (65)

<220>
<221> UNSURE
<222> (96)

<220>
<221> UNSURE
<222> (101)

<400> 18

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Asp | Asp | Asp | Phe | Ser | Val | Pro | Pro | Pro | Ser | Thr | Leu | Asp | Pro | Phe |
| 1 | | | | 5 | | | | 10 | | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Asn | Arg | Thr | Pro | Ala | Ile | Glu | Gly | Leu | Tyr | Glu | Trp | Ala | Lys | Thr |
| | | | | 20 | | | 25 | | | | 30 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Leu | Cys | Leu | Pro | Leu | Ala | Ala | Leu | Arg | Leu | Ala | Leu | Phe | Gly | Leu |
| | | | | | 35 | | | 40 | | | 45 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Leu | Ala | Val | Gly | Tyr | Val | Ala | Thr | Lys | Val | Ala | Leu | Ala | Xaa | Trp |
| | | | | 50 | | | 55 | | | 60 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Asp | Lys | Glu | Asn | Pro | Met | Pro | Lys | Trp | Arg | Cys | Arg | Val | Met | Trp |
| | 65 | | | | 70 | | | 75 | | | 80 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Thr | Arg | Leu | Cys | Ala | Lys | Cys | Ile | Leu | Phe | Ser | Phe | Gly | Tyr | Xaa |
| | | | | 85 | | | | 90 | | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|
| Trp | Ile | Lys | Arg | Xaa | Gly | Lys | Pro | Ala | Pro | Arg | | | | | |
| | | | | 100 | | | 105 | | | | | | | | |

<210> 19
<211> 784
<212> DNA
<213> Oryza sativa

<220>
<221> unsure
<222> (560)

<220>
<221> unsure
<222> (648)

<220>
<221> unsure
<222> (670)

<220>
<221> unsure
<222> (739)

<220>
<221> unsure
<222> (758)

<400> 19

| | | | | | | |
|---------------|-------------|------------|------------|-------------|------------|-----|
| cttctcgatcg | ccgggtggatt | cggccgcgc | tccgcccggc | ccggccggagg | aggaggacga | 60 |
| ggagagggcg | ctccctcggt | ggtgagcatc | cagccacctc | ggcccggtgc | ctcctttcg | 120 |
| catctcggtcc | ccgctgatgtt | gaaagtgggt | gcagggcagg | gcggcagggg | ccatggcggt | 180 |
| cccaactcgatcg | tcgtcgatcg | tcccgctcg | cctcctcttc | ctcctctccg | gcctcaacgc | 240 |

catccaggcc gtcctgttcc tctcgataag gccgttctcg aagagcttgt accggccggat 300
 caacagggttc ttggccgagc tgctgtggct tcagctggtc tggcttgtgg attgggtggc 360
 aggagttaag atacaactgc atgctgatga cgaaaacttac aaggcaatgg ggaatgagca 420
 tgcacttgc atatcaaattc atcggagcga tatcgattgg cttattgggt ggattttggg 480
 cacagcgctc aaggatgcct tggaaagtac acttgctgtt atgaagaaac atccgaatc 540
 cttccaatta ttgggctggn ccatgttgtt tgcagaatac cccttttgg gaaaaggact 600
 gggcaaagga tgaaaagaca ttgaaatggg ggcccccaaa ggtgaanga ctccccaga 660
 catttggcn acccttttgc tttaaggacc cccttaccca aaaaaactcc aacaactcaa 720
 ggagtatctg ttcacagngt tgcaacacca agaaatgnat gatcacgtca aagggattgt 780
 acac 784

<210> 20
<211> 146
<212> PRT
<213> Oryza sativa

<220>
<221> UNSURE
<222> (130)

<400> 20

| | | | |
|-------------------------------------|-----------------|-------------|----|
| Met Ala Val Pro Leu Val Leu Val Val | Leu Pro Leu Gly | Leu Leu Phe | |
| 1 | 5 | 10 | 15 |

| | | |
|---|-------------|----|
| Leu Leu Ser Gly Leu Asn Ala Ile Gln Ala Val Leu Phe | Leu Ser Ile | |
| 20 | 25 | 30 |

| | | |
|---|-------------|----|
| Arg Pro Phe Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg | Phe Leu Ala | |
| 35 | 40 | 45 |

| | | |
|---|-------------|----|
| Glu Leu Leu Trp Leu Gln Leu Val Trp Leu Val Asp Trp | Trp Ala Gly | |
| 50 | 55 | 60 |

| | | | |
|---|-------------|----|----|
| Val Lys Ile Gln Leu His Ala Asp Asp Glu Thr Tyr Lys | Ala Met Gly | | |
| 65 | 70 | 75 | 80 |

| | | |
|---|---------|----|
| Asn Glu His Ala Leu Val Ile Ser Asn His Arg Ser Asp Ile | Asp Trp | |
| 85 | 90 | 95 |

| | | |
|---|-------------|-----|
| Leu Ile Gly Trp Ile Leu Gly Thr Ala Leu Lys Asp Ala | Leu Gly Ser | |
| 100 | 105 | 110 |

| | | |
|---|-------------|-----|
| Thr Leu Ala Val Met Lys Lys His Pro Lys Ser Phe Gln | Leu Leu Gly | |
| 115 | 120 | 125 |

| | | |
|---|-------------|-----|
| Trp Xaa Met Leu Phe Ala Glu Tyr Pro Phe Leu Gly Lys | Gly Leu Gly | |
| 130 | 135 | 140 |

Lys Gly
145

<210> 21
<211> 584
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (17)...(18)

<220>
<221> unsure
<222> (33)

<220>
<221> unsure
<222> (38)...(39)

<220>
<221> unsure
<222> (519)

<220>
<221> unsure
<222> (543)

<220>
<221> unsure
<222> (546)

<220>
<221> unsure
<222> (575)

<400> 21
cgtttgctga cctgacnnncg gttttttttt ttnggggnnc acgggtgttc gttgcgttgt 60
gctctgctcgtccttgg gcctggctg ggctgggctg ggctgggctg ggcattggcta 120
ttcagcagcgc ggccgtgggt gtaccattgg gcctgcttgc ctgcgcctcc ggcctccctt 180
ttaatctcat tcaggcaata tgctatgtcg tcgttaaggcc ggtgtcgaaa agtttgtaca 240
gaaggatcaa ccggtagta gcagagctct tggctgttgg gcttgcgtatgg cttattgtatt 300
ggggcagg agttaagtc caaatattca cagatcatga aaccttcgt ttaatggta 360
aagagcatgc acttgtgata agcaatcaca gaagtgtat tgattggctt gttggatggg 420
ttttagctca cggttcaggt tggcttggca gcactctaag ctgtgtatgaa gaaatcttca 480
aagttctgc cggtcatgg ctggtaatg tggtttcng agtaaacctt tctggagaag 540
aanntnggcc aaagatgaaa gcccattaaa gtcangcatc ccgg 584

<210> 22
<211> 116
<212> PRT
<213> Glycine max

<400> 22
Met Ala Ile Ala Ala Ala Val Val Val Pro Leu Gly Leu Leu Phe
1 5 10 15

Phe Ala Ser Gly Leu Leu Val Asn Leu Ile Gln Ala Ile Cys Tyr Val
20 25 30

Val Val Arg Pro Val Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg Val
35 40 45

Val Ala Glu Leu Leu Trp Leu Glu Leu Val Trp Leu Ile Asp Trp Trp
50 55 60

Ala Gly Val Lys Val Gln Ile Phe Thr Asp His Glu Thr Phe Arg Leu
65 70 75 80

Met Gly Lys Glu His Ala Leu Val Ile Ser Asn His Arg Ser Asp Ile
85 90 95

Asp Trp Leu Val Gly Trp Val Ser Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110

Ser Thr Leu Ser
 115

<210> 23
 <211> 570
 <212> DNA
 <213> Triticum aestivum

<220>
 <221> unsure
 <222> (510)

<220>
 <221> unsure
 <222> (516)

<220>
 <221> unsure
 <222> (518)

<400> 23
 gagaggagac gcggcgccgg ccatggcgat tcccctcggt ctgcgtcctgc tcccgctcgg 60
 cctccttc ctcctctccg gcctcggtcgt caacactgtc cagggcgat tttcttgac 120
 gataaggcca ttctcgaaac gattgttaccg gcagatcaac gtattcctgg ccgagttgtt 180
 gtggcttcag ctgatctggc ttgtggactg gtgggcaggt attaagggtac aggtgtatgc 240
 ggatccagaa acttggaaac taatggcaa agagcacgcc ctttcataat ccaatcatcg 300
 aagtgcattt gattggctgg ttggatggat ttttagcacag cgttcaggat gtcttggaaag 360
 cgcaataagct ataatgaaga aatctcaaa gttccttcca gtttattgggtt ggtccatgtg 420
 gtttgcagaa tactctttt gagaactg gcaaaggatg aaaaacacta aatcgggtct 480
 caaggtgaaa actccagata ttggctgccc tttgttangg tcaaattact cacaacttt 540
 acagtaagaa atcatccaag ggttgcacgc 570

<210> 24
 <211> 160
 <212> PRT
 <213> Triticum aestivum

<400> 24
 Met Ala Ile Pro Leu Val Leu Val Leu Pro Leu Gly Leu Leu Phe
 1 5 10 15

Leu Leu Ser Gly Leu Val Val Asn Thr Val Gln Ala Val Leu Phe Leu
 20 25 30

Thr Ile Arg Pro Phe Ser Lys Arg Leu Tyr Arg Gln Ile Asn Val Phe
 35 40 45

Leu Ala Glu Leu Leu Trp Leu Gln Leu Ile Trp Leu Val Asp Trp Trp
 50 55 60

Ala Gly Ile Lys Val Gln Val Tyr Ala Asp Pro Glu Thr Trp Lys Leu
 65 70 75 80

Met Gly Lys Glu His Ala Leu Leu Ile Ser Asn His Arg Ser Asp Ile
 85 90 95

Asp Trp Leu Val Gly Trp Ile Leu Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110

Ser Ala Ile Ala Ile Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
 115 120 125

Gly Trp Ser Met Trp Phe Ala Glu Tyr Ser Phe Gly Glu Asn Trp Gln
 130 135 140

Arg Met Lys Asn Thr Lys Ser Gly Leu Lys Val Lys Thr Pro Asp Ile
 145 150 155 160

<210> 25

<211> 1337

<212> DNA

<213> Catalpa speciosa

<400> 25

| | | | | | | |
|--------------|-------------|-------------|-------------|--------------|--------------|------|
| gcacgagagg | ctaaaggaca | atgagcaagc | taaaaacatc | cagctccgaa | ttggatttgg | 60 |
| atcaccccaa | tatcgaaagac | tatcttccat | ccggatccat | tcaagagcct | cacggcaagc | 120 |
| tccgcctgcg | tgatttgcgc | gatatttcac | caactctaac | tgaggcagct | ggtgcatttg | 180 |
| ttgatgactc | cttcacgaga | tgcttcaagt | caaatccgccc | agaaccctgg | aactggaaca | 240 |
| tatatttgtt | tcctttgtgg | tgcttaggag | ttgttgcag | atatggtctt | cttttccccct | 300 |
| taagggtaat | agtgttgaca | ataggatgg | ttatatttct | ctcatgctat | ttccctgtgc | 360 |
| atttcctgtt | aaaagggcat | gacaaatig | aaaaaaaatt | agagagaggt | ctagtggagt | 420 |
| tgatgtgcag | ttttttgtt | gcatcatgga | ctggggtgt | caagtaccat | ggtccgcggc | 480 |
| ccagcatgcg | gcctaagcag | gtttttgtgg | ctaattcacac | atccatgatt | gatttcatttgc | 540 |
| tttttggaaaca | aatgactgca | tttgcagtga | ttatgcagaa | gcatcctggg | tgggttaggac | 600 |
| tattgcagag | cactatttgc | gagagtctag | gatgttatctg | gttcaaccgg | tcagagtcca | 660 |
| aggaccgtga | aattttgttca | aaaaagctaa | gagatcatgt | ccatggcgct | gataataatc | 720 |
| ctctcttat | attcccgaa | ggaacatgtg | tgaataacca | ctacactgtg | atgtttaaga | 780 |
| agggtgtcatt | tgaacttgg | tgcactgtct | gtccaatcgc | aatcaagttat | aacaagattt | 840 |
| tttgtggatgc | cttctggaaac | agcagaaagc | aatcctttac | aatgcacttg | ttgcagctta | 900 |
| tgacatctgt | ggctgttg | tgtgtatgtt | ggtacctgg | gcctcaaaat | ctaaaacctg | 960 |
| gggaaacacc | aatttgaattt | gctgagaggg | tgaggggcat | tatttctgtt | cgagcaggcc | 1020 |
| ttaagaaggt | gccgtggat | ggatatttga | agtaactctcg | ccccagccca | aagcatcg | 1080 |
| agcgaaagca | acaaagcttc | gcagagtctag | ttctccatca | ccttggaaagag | aaatagattt | 1140 |
| aagataaata | attttggat | ttactgtctt | caatttggta | gatcaagttt | gttagctgtt | 1200 |
| ttgaaattca | atcttatttgc | tcactataaa | gaggatttca | gttccctcaat | tgacataatg | 1260 |
| aaattccctt | gatacgtcgt | tgaagaggaa | aatacaatat | gaagtgttga | aaaaaaaaaa | 1320 |
| aaaaaaaaaa | aaaaaaaaaa | | | | | 1337 |

<210> 26

<211> 371

<212> PRT

<213> Catalpa speciosa

<400> 26

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Lys | Leu | Lys | Thr | Ser | Ser | Ser | Glu | Leu | Asp | Leu | Asp | His | Pro |
| 1 | | | | 5 | | | | | 10 | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ile | Glu | Asp | Tyr | Leu | Pro | Ser | Gly | Ser | Ile | Gln | Glu | Pro | His | Gly |
| | | | | 20 | | | | 25 | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Leu | Arg | Leu | Arg | Asp | Leu | Leu | Asp | Ile | Ser | Pro | Thr | Leu | Thr | Glu |
| | | | | 35 | | | | 40 | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ala | Gly | Ala | Ile | Val | Asp | Asp | Ser | Phe | Thr | Arg | Cys | Phe | Lys | Ser |
| | | | | 50 | | | | 55 | | | | 60 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Pro | Pro | Glu | Pro | Trp | Asn | Trp | Asn | Ile | Tyr | Leu | Phe | Pro | Leu | Trp |
| 65 | | | | | 70 | | | | 75 | | | | | | 80 |
| Cys | Leu | Gly | Val | Val | Val | Arg | Tyr | Gly | Leu | Leu | Phe | Pro | Leu | Arg | Val |
| | | | 85 | | | | | | 90 | | | | | | 95 |
| Ile | Val | Leu | Thr | Ile | Gly | Trp | Ile | Ile | Phe | Leu | Ser | Cys | Tyr | Phe | Pro |
| | | | 100 | | | | | 105 | | | | | | | 110 |
| Val | His | Phe | Leu | Leu | Lys | Gly | His | Asp | Lys | Leu | Arg | Lys | Lys | Leu | Glu |
| | | | 115 | | | | | 120 | | | | | | | 125 |
| Arg | Gly | Leu | Val | Glu | Leu | Met | Cys | Ser | Phe | Phe | Val | Ala | Ser | Trp | Thr |
| | 130 | | | | | 135 | | | | | | | | | 140 |
| Gly | Val | Val | Lys | Tyr | His | Gly | Pro | Arg | Pro | Ser | Met | Arg | Pro | Lys | Gln |
| | 145 | | | | | 150 | | | | 155 | | | | | 160 |
| Val | Phe | Val | Ala | Asn | His | Thr | Ser | Met | Ile | Asp | Phe | Ile | Val | Leu | Glu |
| | 165 | | | | | 170 | | | | | | | | | 175 |
| Gln | Met | Thr | Ala | Phe | Ala | Val | Ile | Met | Gln | Lys | His | Pro | Gly | Trp | Val |
| | 180 | | | | | 185 | | | | | | | | | 190 |
| Gly | Leu | Leu | Gln | Ser | Thr | Ile | Leu | Glu | Ser | Leu | Gly | Cys | Ile | Trp | Phe |
| | 195 | | | | | 200 | | | | | | | | | 205 |
| Asn | Arg | Ser | Glu | Ser | Lys | Asp | Arg | Glu | Ile | Val | Ala | Lys | Lys | Leu | Arg |
| | 210 | | | | | 215 | | | | | | | | | 220 |
| Asp | His | Val | His | Gly | Ala | Asp | Asn | Asn | Pro | Leu | Leu | Ile | Phe | Pro | Glu |
| | 225 | | | | | 230 | | | | 235 | | | | | 240 |
| Gly | Thr | Cys | Val | Asn | Asn | His | Tyr | Thr | Val | Met | Phe | Lys | Lys | Gly | Ala |
| | 245 | | | | | 250 | | | | | | | | | 255 |
| Phe | Glu | Leu | Gly | Cys | Thr | Val | Cys | Pro | Ile | Ala | Ile | Lys | Tyr | Asn | Lys |
| | 260 | | | | | 265 | | | | 270 | | | | | |
| Ile | Phe | Val | Asp | Ala | Phe | Trp | Asn | Ser | Arg | Lys | Gln | Ser | Phe | Thr | Met |
| | 275 | | | | | 280 | | | | | | | | | 285 |
| His | Leu | Leu | Gln | Leu | Met | Thr | Ser | Trp | Ala | Val | Val | Cys | Asp | Val | Trp |
| | 290 | | | | | 295 | | | | | | | | | 300 |
| Tyr | Leu | Glu | Pro | Gln | Asn | Leu | Lys | Pro | Gly | Glu | Thr | Pro | Ile | Glu | Phe |
| | 305 | | | | | 310 | | | | 315 | | | | | 320 |
| Ala | Glu | Arg | Val | Arg | Gly | Ile | Ile | Ser | Val | Arg | Ala | Gly | Leu | Lys | Lys |
| | 325 | | | | | 330 | | | | | | | | | 335 |
| Val | Pro | Trp | Asp | Gly | Tyr | Leu | Lys | Tyr | Ser | Arg | Pro | Ser | Pro | Lys | His |
| | 340 | | | | | 345 | | | | | | | | | 350 |
| Arg | Glu | Arg | Lys | Gln | Gln | Ser | Phe | Ala | Glu | Ser | Val | Leu | His | His | Leu |
| | 355 | | | | | 360 | | | | | | | | | 365 |
| Glu | Glu | Lys | | | | | | | | | | | | | |
| | 370 | | | | | | | | | | | | | | |

<210> 27
<211> 1582
<212> DNA
<213> Zea mays

<400> 27

```
cctcgcccca tcgcggaccc ttccctcgccg ggcgtccccat ctcatcgccg gcggggcgtgc 60
ggcccggtggc cgaagccctt aggcgatggc gacccgtct gtggcggcgg acatggagct 120
ggaccggcca aacctggagg actacccc gcccgaactcg ctcccgccagg aggcccccgg 180
gaatctccat ctgcgcgatc tgcgtggacat ctgcgggtg ctacccggagg cagcgggtgc 240
cattgtcgat gactcctca cacggtgctt taagtcaa at tctccagagc catggaaattt 300
gaacatataat ctgtccccc tatggtgctt tggtgttagta ataagatatg gattactctt 360
cccactgagg tccttaacgc ttgcaatagg atggttagca tttttgtct cctttttcc 420
tgtccatttc ctattgaaag gtcaagacaa gttgagaagt aaaattgaga ggaagttgg 480
tgaatgatg tgcagtgtt ttgttgcctt atggacttga gttatcaagt atcatggacc 540
acgcggcaacg acacgcacctc atcaggattt cggtgcaaaac catacatcga tgatagattt 600
cattattctg gagcaatgatc cagcatttgc tgcattcatg cagaaggatc ctggatgggt 660
tggattttt cagaagacta tctggaaag tgcgggtgc atctggttt atcgtaatga 720
tctccgggac cgtgaaggta cggcacggaa gttacgttatc catgttcaac aaccagacaa 780
caatccctcg ttgattttcc cggaaaggaaac ttgtgtgaac aaccagtaca cggtcatgtt 840
caagaagggt gcctttgagc ttggctgcgc tgcattgtcca atagctatca agtacaataa 900
aatatttgc gatgcctttt ggaacagttaa gaagcaatct tttacaatgc acttggccg 960
gctgatgaca tcatgggtt ttgtgtgtga tggttggtac ttaccccttc aatatctgag 1020
ggaggggagac acggcaattt cattgtgtga gagagtaagg gacatgatag ctgctagagc 1080
tggactaaag aagggttccctt gggatggcta tctgaaacac aaccgtccta gtcccaaaca 1140
caactgaagag aaacaacgca tatttgcga atctgtttt atgagactgg aggagaaatg 1200
aaggggacgta aaggcgatata agtgcactt gttagggtt tacatgcagc taccttgtaa 1260
ttcggttggc ttccagaaaa aaaaaaggtaa gcctgggaca cgtcaagtga ccacccctcgt 1320
tttgggtttaa atttggtaact agtttgatag gattattgtt atgtacttat caggaaaaga 1380
atttcagta tgcgttttgg ctgcccattt aatgataatgtt cagtgattaa caccgaagca 1440
ttgtgtctc gtgagatgtt gtgttggctt taatataattt acggtactgtt accatggttt 1500
aaatgtgattt attgaagcaaa tgcgtatggaa ttagctggctt aagaaaaaaaaaaaaaaa 1560
aaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa ag 1582
```

<210> 28
<211> 371
<212> PRT
<213> Zea mays

<400> 28

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Thr | Ser | Ser | Val | Ala | Ala | Asp | Met | Glu | Leu | Asp | Arg | Pro | Asn |
| 1 | | | | | 5 | | | | 10 | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Glu | Asp | Tyr | Leu | Pro | Pro | Asp | Ser | Leu | Pro | Gln | Glu | Ala | Pro | Arg |
| | | | | 20 | | | | 25 | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Leu | His | Leu | Arg | Asp | Leu | Leu | Asp | Ile | Ser | Pro | Val | Leu | Thr | Glu |
| | | | | | 35 | | | 40 | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ala | Gly | Ala | Ile | Val | Asp | Asp | Ser | Phe | Thr | Arg | Cys | Phe | Lys | Ser |
| | | | | | 50 | | 55 | | | 60 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Pro | Glu | Pro | Trp | Asn | Trp | Asn | Ile | Tyr | Leu | Phe | Pro | Leu | Trp |
| | | | | | 65 | | 70 | | 75 | | | 80 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Phe | Gly | Val | Val | Ile | Arg | Tyr | Gly | Leu | Leu | Phe | Pro | Leu | Arg | Ser |
| | | | | | 85 | | | 90 | | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Thr | Leu | Ala | Ile | Gly | Trp | Leu | Ala | Phe | Phe | Ala | Ala | Phe | Phe | Pro |
| | | | | | 100 | | | 105 | | | | 110 | | | |

Val His Phe Leu Leu Lys Gly Gln Asp Lys Leu Arg Ser Lys Ile Glu
 115 120 125

Arg Lys Leu Val Glu Met Met Cys Ser Val Phe Val Ala Ser Trp Thr
 130 135 140

Gly Val Ile Lys Tyr His Gly Pro Arg Pro Ser Thr Arg Pro His Gln
 145 150 155 160

Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile Ile Leu Glu
 165 170 175

Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro Gly Trp Val
 180 185 190

Gly Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly Cys Ile Trp Phe
 195 200 205

Asn Arg Asn Asp Leu Arg Asp Arg Glu Val Thr Ala Arg Lys Leu Arg
 210 215 220

Asp His Val Gln Gln Pro Asp Asn Asn Pro Leu Leu Ile Phe Pro Glu
 225 230 235 240

Gly Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe Lys Lys Gly Ala
 245 250 255

Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile Lys Tyr Asn Lys
 260 265 270

Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln Ser Phe Thr Met
 275 280 285

His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val Cys Asp Val Trp
 290 295 300

Tyr Leu Pro Pro Gln Tyr Leu Arg Glu Gly Glu Thr Ala Ile Ala Phe
 305 310 315 320

Ala Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala Gly Leu Lys Lys
 325 330 335

Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro Ser Pro Lys His
 340 345 350

Thr Glu Glu Lys Gln Arg Ile Phe Ala Glu Ser Val Leu Met Arg Leu
 355 360 365

Glu Glu Lys
 370

<210> 29
<211> 1422
<212> DNA
<213> Oryza sativa

<400> 29

gcacgagatc actgcgaaga tttcctcgcc ggccggcgag gggatcgacg gagggggggga 60
tggcgacctc gtcgggtggcg gggacatcg agctggaccg gccgaacctg gaggactacc 120

| | | | | | | |
|-------------|------------|--------------|-------------|-------------|-------------|------|
| tcccatccga | ctcgctgccg | caggagttcc | ccaggaatct | ccatctgcgc | gatctgctgg | 180 |
| acatctcgcc | ggtgctact | gaagcagcgg | gcgcacatgt | cgatgattca | ttcacacgtt | 240 |
| gctttaagtc | aaattctcca | gagccatgga | attggaacat | ttatccgtt | ccatttgtgtt | 300 |
| gcttggagt | agtgataaga | tacggaatac | tattccgtt | gaggggccta | actcttctag | 360 |
| ttggatggtt | agcattcttt | gctgcctttt | ttcctgtaca | tttcttattt | aaaggtaaaa | 420 |
| agatgagaag | taaaatagag | agaaaagctgg | ttgaaatgtat | gtcagtgtt | tttgggttgc | 480 |
| cttggactgg | agtgatcaag | tatcatggc | ctcgcccaag | cacacggcct | catcaggtat | 540 |
| tttgtcaaa | ccatacatcg | atgatagatt | tcattattct | ggagcagatg | acagcatttgc | 600 |
| ctgtcattat | gcaaagcat | cctggatggg | ttggatttat | tcagaagact | atcttgaaa | 660 |
| gtgttggttg | catctggttt | aatcgcaatg | atctcaagga | tcgtgaagtgc | gttgcaaaaa | 720 |
| agttacgaga | tcatgttcaa | catccagaca | gcaatccctt | cctgattttc | cctgaaggaa | 780 |
| cttgtttaa | caaccagtac | actgtcatgt | tcaagaaggg | tgcttttgag | cttggctgtt | 840 |
| ctgtatgccc | aatagctatc | aaatacaata | aaatatttgc | tgtgccttc | tgaaatagta | 900 |
| agaagcaatc | gtttacaatg | cacttggta | ggcttatgac | atcatgggca | gttgggtgt | 960 |
| atgtatggta | cttggagcct | cagtatctga | gggatggaga | aacagcaatt | gaatttgctg | 1020 |
| aaagagtaag | agacatgata | gctgctagag | ctggcttaa | gaagggtccg | tgggacgggt | 1080 |
| atctgaaaca | caaccgcctt | agtcccaaac | acactgaaga | gaagcagcgc | atcttgctg | 1140 |
| actctgtgtt | gcggagactg | gaggaaagct | aaacagatata | caatcaactc | tgggtgtcat | 1200 |
| tggtgagtcc | aggttactaa | tgtccttagtgc | tgtatctggg | tctctggagt | atgtggaaat | 1260 |
| taccactgca | gttttggttt | aaattgttttgc | cagttgaca | gaatcaacat | ttaataagcct | 1320 |
| gtattagcca | agattttatg | attggtagg | gttaacacat | aatattata | ccttcccaaa | 1380 |
| tgatgttatta | atacttaccc | tcaaaaaaaaaa | aaaaaaaaaa | ac | | 1422 |

<210> 30

<211> 370

<212> PRT

<213> Oryza sativa

<400> 30

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Thr | Ser | Ser | Val | Ala | Gly | Asp | Ile | Glu | Leu | Asp | Arg | Pro | Asn |
| 1 | | | | | 5 | | | | 10 | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Glu | Asp | Tyr | Leu | Pro | Ser | Asp | Ser | Leu | Pro | Gln | Glu | Phe | Pro | Arg |
| | | | 20 | | | | | 25 | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Leu | His | Leu | Arg | Asp | Leu | Leu | Asp | Ile | Ser | Pro | Val | Leu | Thr | Glu |
| | | 35 | | | | | | 40 | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ala | Gly | Ala | Ile | Val | Asp | Asp | Ser | Phe | Thr | Arg | Cys | Phe | Lys | Ser |
| | | 50 | | | | 55 | | | | 60 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ser | Pro | Glu | Pro | Trp | Asn | Trp | Asn | Ile | Tyr | Leu | Phe | Pro | Leu | Trp |
| | | 65 | | | | 70 | | | 75 | | | | 80 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Leu | Gly | Val | Val | Ile | Arg | Tyr | Gly | Ile | Leu | Phe | Pro | Leu | Arg | Gly |
| | | 85 | | | | 90 | | | | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Thr | Leu | Leu | Val | Gly | Trp | Leu | Ala | Phe | Phe | Ala | Ala | Phe | Phe | Pro |
| | | 100 | | | | | 105 | | | | 110 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | His | Phe | Leu | Leu | Lys | Gly | Gln | Lys | Met | Arg | Ser | Lys | Ile | Glu | Arg |
| | | 115 | | | | | 120 | | | | 125 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Leu | Val | Glu | Met | Met | Cys | Ser | Val | Phe | Val | Ala | Ser | Trp | Thr | Gly |
| | | 130 | | | | 135 | | | | | 140 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Ile | Lys | Tyr | His | Gly | Pro | Arg | Pro | Ser | Thr | Arg | Pro | His | Gln | Val |
| | | 145 | | | | 150 | | | | 155 | | | 160 | | |

Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile Ile Leu Glu Gln
 165 170 175

Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro Gly Trp Val Gly
 180 185 190

Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly Cys Ile Trp Phe Asn
 195 200 205

Arg Asn Asp Leu Lys Asp Arg Glu Val Val Ala Lys Lys Leu Arg Asp
 210 215 220

His Val Gln His Pro Asp Ser Asn Pro Leu Leu Ile Phe Pro Glu Gly
 225 230 235 240

Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe Lys Lys Gly Ala Phe
 245 250 255

Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile Lys Tyr Asn Lys Ile
 260 265 270

Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln Ser Phe Thr Met His
 275 280 285

Leu Val Arg Leu Met Thr Ser Trp Ala Val Val Cys Asp Val Trp Tyr
 290 295 300

Leu Glu Pro Gln Tyr Leu Arg Asp Gly Glu Thr Ala Ile Glu Phe Ala
 305 310 315 320

Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala Gly Leu Lys Lys Val
 325 330 335

Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro Ser Pro Lys His Thr
 340 345 350

Glu Glu Lys Gln Arg Ile Phe Ala Asp Ser Val Leu Arg Arg Leu Glu
 355 360 365

Glu Ser
 370

<210> 31

<211> 1392

<212> DNA

<213> Sorghum

<400> 31

gcacgagcca ggaatctcca tctgcgcgat ctgcttgaca tctcgccggc gctaaccgag 60
 gcagcgggtg ccatagtoga tgattcatc acgcgcgtgc ttaagtcgaa ttctccagaa 120
 ccatggaact ggaacatata tttgttccct ttatgggtct tcggtgttagt aattcgatat 180
 ggattactct tcccactgag gtccttaacg cttgcaatag gatgggttagc atttttgtct 240
 gccttttcc ccgtgcattt cctattgaaa ggtcaagaca agttgagaaa taaaattgag 300
 aggaagttgg ttgaaatgtat gtgcagtgtt tttgttgcatt catggactgg agtgatcaag 360
 taccatggac cacgcggcaag cacacgacct catcaggat ttgttgcataa ccatacatca 420
 atgatagatt tcattattct ggagcaatg acagcatgtt ctgtcatcat gcagaagcat 480
 cctggatggg ttggatttat tcagaagact atcttggaaa gtgtgggttg catctgttt 540
 aaccgtaatg atctccggga tcgtgaagtt acggcacgga agttgcgtga tcattgtcaa 600
 catccagaca aaaaccctct cttgattttc ccagaagaa cttgtgttaa caaccagtat 660
 acggtcatgt tcaagaaggg tgcctttgag cttgggtgtg ctgtctgtcc aatagctatc 720

aaatacaata aaatatattgt tgatgccttt tggAACAGTA agaAGCAATC ttttACGATG 780
 cacttggtcc ggttGATGAC atcatGGGCT gttgtgtgtg atgtttggta CTTGGAGCCT 840
 caatatCTGA gggAGGGAGA gACTGCAATT GCGTTGCTG AGAGAGTAAG GGACATGATA 900
 gcagctAGAG CTGGTCTAA gaaggTCCCg TGGGATGGCT ATCTGAAACA CAACCGCCCT 960
 agtcccAAC acaccGAAGA gaagcaACGC atattGCCG aacttgtctt gaggagACTA 1020
 gagggAGAAAT gaagAGAGACAT caaacACTAC aagcgcATTt ggTTAGTGGT ttaccGTTCA 1080
 gctacCTTGT aattcggttg gctccccgaa aaaaaaaaAGT ccgggacacg tcaagtGCC 1140
 agtcAGTTT tggTTGAAAT ttattAGAAA ttTGACAGAA ttggTAGTGT gaacttACCA 1200
 agaaAGGAAG aatAGCCGA tggTTGTTGg CTGTTCAATT tatGATTGGT taggaATTGA 1260
 cacttGAAAC acggTACTCT attcAGAGGC tggTCCGTA tttatGAATC gacgatGTA 1320
 tggTTTAAAT tcATGTGATT attGATTCAA taatATGAGT agattAAAAA aaaaaaaaaa 1380
 aaaaaaaaaaa aa 1392

<210> 32

<211> 343

<212> PRT

<213> Sorghum

<400> 32

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Arg | Ala | Arg | Asn | Leu | His | Leu | Arg | Asp | Leu | Leu | Asp | Ile | Ser | Pro |
| 1 | | | | 5 | | | | 10 | | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Leu | Thr | Glu | Ala | Ala | Gly | Ala | Ile | Val | Asp | Asp | Ser | Phe | Thr | Arg |
| | | | 20 | | | | | 25 | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Phe | Lys | Ser | Asn | Ser | Pro | Glu | Pro | Trp | Asn | Trp | Asn | Ile | Tyr | Leu |
| | | | 35 | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Pro | Leu | Trp | Cys | Phe | Gly | Val | Val | Ile | Arg | Tyr | Gly | Leu | Leu | Phe |
| | | | 50 | | | | 55 | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Leu | Arg | Ser | Leu | Thr | Leu | Ala | Ile | Gly | Trp | Leu | Ala | Phe | Phe | Ala |
| | | | 65 | | | | 70 | | | 75 | | | 80 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Phe | Phe | Pro | Val | His | Phe | Leu | Leu | Lys | Gly | Gln | Asp | Lys | Leu | Arg |
| | | | | 85 | | | | 90 | | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Lys | Ile | Glu | Arg | Lys | Leu | Val | Glu | Met | Met | Cys | Ser | Val | Phe | Val |
| | | | 100 | | | | 105 | | | | 110 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ser | Trp | Thr | Gly | Val | Ile | Lys | Tyr | His | Gly | Pro | Arg | Pro | Ser | Thr |
| | | | 115 | | | | 120 | | | | 125 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Pro | His | Gln | Val | Phe | Val | Ala | Asn | His | Thr | Ser | Met | Ile | Asp | Phe |
| | | | 130 | | | | 135 | | | | 140 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ile | Leu | Glu | Gln | Met | Thr | Ala | Phe | Ala | Val | Ile | Met | Gln | Lys | His |
| | | | 145 | | | | 150 | | | 155 | | | 160 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Gly | Trp | Val | Gly | Phe | Ile | Gln | Lys | Thr | Ile | Leu | Glu | Ser | Val | Gly |
| | | | | 165 | | | | 170 | | | | 175 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Ile | Trp | Phe | Asn | Arg | Asn | Asp | Leu | Arg | Asp | Arg | Glu | Val | Thr | Ala |
| | | | | 180 | | | | 185 | | | | 190 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Lys | Leu | Arg | Asp | His | Val | Gln | His | Pro | Asp | Lys | Asn | Pro | Leu | Leu |
| | | | 195 | | | | 200 | | | | 205 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Phe | Pro | Glu | Gly | Thr | Cys | Val | Asn | Asn | Gln | Tyr | Thr | Val | Met | Phe |
| | | | 210 | | | | 215 | | | | 220 | | | | |

Lys Lys Gly Ala Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile
 225 230 235 240

Lys Tyr Asn Lys Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln
 245 250 255

Ser Phe Thr Met His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val
 260 265 270

Cys Asp Val Trp Tyr Leu Glu Pro Gln Tyr Leu Arg Glu Gly Glu Thr
 275 280 285

Ala Ile Ala Phe Ala Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala
 290 295 300

Gly Leu Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro
 305 310 315 320

Ser Pro Lys His Thr Glu Glu Lys Gln Arg Ile Phe Ala Glu Ser Val
 325 330 335

Leu Arg Arg Leu Glu Glu Lys
 340

<210> 33

<211> 1466

<212> DNA

<213> Glycine max

<400> 33

| | | | | | |
|-------------|------------|------------|------------|-------------|------|
| tctctctctc | tctctctctc | tctctctctg | gacaaaattg | ccctccatca | 60 |
| ctttccttgt | tagagttgt | ttctgcacc | taccatgcaa | ttcctcacct | 120 |
| tctattgcca | cgttggatc | aaaaagtcta | gtttaaccac | acgtttgtgg | 180 |
| agcgtaacga | agatgaatgg | cattggaaaa | ctcaaatcgt | cgagttctga | 240 |
| cacattgaag | attacctacc | ttctggatcc | agtgttcaac | aagaacggca | 300 |
| cgactgtgt | atttgctaga | catttctcct | agtctatctg | aggcagcacg | 360 |
| gatgatacat | tcacaaggt | tttcaagtca | aatcctccag | tgccattgtta | 420 |
| tatttgtttc | cttgtggtg | ctgtggagtt | gtggttcgat | atttgatttt | 480 |
| aggattcttag | tgttggcatt | aggatggatt | atatttctt | gttccctatt | 540 |
| tccctccctga | aaggaaatga | tgatttgagg | aaaaagattt | tccagtgcac | 600 |
| atgtgcagtt | tctttgttgc | atcatggact | ggggttgtca | agtaccatgg | 660 |
| agtatccgac | caaaacaggt | ttttgtggcc | aatcatactt | gccaagacct | 720 |
| ttagaacaga | tgactgcatt | tgctgttatt | atgcagaagc | tttcattatc | 780 |
| ttgcagagca | ccattttgga | gagtgtgggg | tgtatctgt | atcctggatg | 840 |
| gatcgagaaa | ttgtggcaag | gaaatggagg | gatcatgtcc | ggggagctaa | 900 |
| cttctaatat | ttcctgaagg | aacttgtta | aataatcact | caataaccct | 960 |
| ggtcatttg | aacttggctg | cacaatttgc | actctgtcat | tttcaagaag | 1020 |
| gtcgatgctt | tttggatag | tcgaaagcaa | tttcaatctt | gttcaagatg | 1080 |
| acatcttggg | ctgtagttt | tgatgtttgg | tacttggagc | tttcaatctt | 1140 |
| gagacaccca | ttgaatttgc | agagagagtt | tttcaatctt | tttcaatctt | 1200 |
| aaaaaggttc | cttggatgg | agagacataa | tttcaatctt | tttcaatctt | 1260 |
| ggaaaagcaac | aaatattcgc | tgagttctgt | tttcaatctt | tttcaatctt | 1320 |
| tctttttact | tttctcgtaa | tgattttctc | tttcaatctt | tttcaatctt | 1380 |
| tgtatatacat | tttctcgtaa | tttcaatctt | tttcaatctt | tttcaatctt | 1440 |
| aaaaaaaaact | tttcaatctt | tttcaatctt | tttcaatctt | tttcaatctt | 1466 |

<210> 34

<211> 373

<212> PRT

<213> Glycine max

<400> 34

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asn | Gly | Ile | Gly | Lys | Leu | Lys | Ser | Ser | Ser | Ser | Glu | Leu | Asp | Leu |
| 1 | | | | | 5 | | | 10 | | | | | 15 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Ile | Glu | Asp | Tyr | Leu | Pro | Ser | Gly | Ser | Ser | Val | Gln | Gln | Glu | Arg |
| | | | | | 20 | | | 25 | | | | 30 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | Gly | Lys | Leu | Arg | Leu | Cys | Asp | Leu | Leu | Asp | Ile | Ser | Pro | Ser | Leu |
| | | | | | 35 | | | 40 | | | 45 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Glu | Ala | Ala | Arg | Ala | Ile | Val | Asp | Asp | Thr | Phe | Thr | Arg | Cys | Phe |
| | | | | | 50 | | | 55 | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Ser | Asn | Pro | Pro | Glu | Pro | Trp | Asn | Trp | Asn | Val | Tyr | Leu | Phe | Pro |
| 65 | | | | | 70 | | | | | 75 | | | 80 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Trp | Cys | Cys | Gly | Val | Val | Val | Arg | Tyr | Leu | Ile | Leu | Phe | Pro | Ile |
| | | | | | 85 | | | 90 | | | 95 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ile | Leu | Val | Leu | Ala | Leu | Gly | Trp | Ile | Ile | Phe | Leu | Ser | Ala | Phe |
| | | | | | 100 | | | 105 | | | 110 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Pro | Val | His | Ser | Leu | Leu | Lys | Gly | Asn | Asp | Asp | Leu | Arg | Lys | Lys |
| | | | | | 115 | | | 120 | | | 125 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Glu | Arg | Cys | Leu | Val | Glu | Met | Met | Cys | Ser | Phe | Phe | Val | Ala | Ser |
| 130 | | | | | 135 | | | | | 140 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Thr | Gly | Val | Val | Lys | Tyr | His | Gly | Pro | Arg | Pro | Ser | Ile | Arg | Pro |
| 145 | | | | | 150 | | | 155 | | | 160 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Gln | Val | Phe | Val | Ala | Asn | His | Thr | Ser | Met | Ile | Asp | Phe | Ile | Ile |
| | | | | | 165 | | | 170 | | | 175 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Glu | Gln | Met | Thr | Ala | Phe | Ala | Val | Ile | Met | Gln | Lys | His | Pro | Gly |
| | | | | | 180 | | | 185 | | | 190 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Val | Gly | Leu | Leu | Gln | Ser | Thr | Ile | Leu | Glu | Ser | Val | Gly | Cys | Ile |
| | | | | | 195 | | | 200 | | | 205 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Phe | Asn | Arg | Thr | Glu | Ala | Lys | Asp | Arg | Glu | Ile | Val | Ala | Arg | Lys |
| 210 | | | | | 215 | | | | | 220 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Leu | Arg | Asp | His | Val | Leu | Gly | Ala | Asn | Asn | Pro | Leu | Leu | Ile | Phe | |
| 225 | | | | | 230 | | | 235 | | | 240 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Glu | Gly | Thr | Cys | Val | Asn | Asn | His | Tyr | Ser | Val | Met | Phe | Lys | Lys |
| | | | | | 245 | | | 250 | | | 255 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Ala | Phe | Glu | Leu | Gly | Cys | Thr | Ile | Cys | Pro | Val | Ala | Ile | Lys | Tyr |
| | | | | | 260 | | | 265 | | | 270 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Lys | Ile | Phe | Val | Asp | Ala | Phe | Trp | Asn | Ser | Arg | Lys | Gln | Ser | Phe |
| | | | | | 275 | | | 280 | | | 285 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Thr | His | Leu | Leu | Gln | Leu | Met | Thr | Ser | Trp | Ala | Val | Val | Cys | Asp |
| | | | | | 290 | | | 295 | | | 300 | | | | |

Val Trp Tyr Leu Glu Pro Gln Asn Leu Lys Pro Gly Glu Thr Pro Ile
 305 310 315 320

Glu Phe Ala Glu Arg Val Arg Asp Ile Ile Ser His Arg Ala Gly Leu
 325 330 335

Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys Tyr Ser Arg Pro Ser Pro
 340 345 350

Lys His Arg Glu Gly Lys Gln Gln Ile Phe Ala Glu Ser Val Leu Arg
 355 360 365

Arg Phe Glu Glu Lys
 370

<210> 35

<211> 1384

<212> DNA

<213> Catalpa speciosa

<400> 35

gcacgaggta ggtttctgtc gaggattttg ttgtttgtt tcgggttcta ttggatttgt 60
 gaaaccagta agggaaattga ggttgatggg cagggaaata atgagtctgc atcttagaat 120
 cggtgtgaag aggtggaagg acctggggct attgtatcca atcatatatc ttatatacat 180
 atccctgtatc acatgtcttc ctcttccca agtttcgtt ccaagagatc cgtcgctaaa 240
 ctcccccttg ttggtcttgt gagcaagtgt cttgggttgt tatatgtaca gcgtgagttt 300
 aagtgcgtcg atttcaaggg ggtatcaggt gttgtcactg aaagaattca agaagctcat 360
 caaaaataagt ttgctccaaa gatgataatt tcccagaag gcacaactac aaatggggac 420
 ttccctcccttc cattcaagac tggtgcattt ttggcaaagg ctccagttact ttctgtcatt 480
 ttaagatatt cgtaccagag atttagtccc gcgtgggact ctatttctgg ggctcgccat 540
 gtgattcttc ttctctgtca gtttgttaat tacattgaag tgacacattt gcctgtttat 600
 catccgtccg aacaagaaaa ggaagatccc aagcttttcg ctgaaaatgt taggettctg 660
 atggctcgtg agggtaattt gatttttcg gatattggat tggcggagaa acgagtttat 720
 catgctgctc tcaatggtt actttgtcaa agataatcca gtttcgttat attgattgtt 780
 taaatgtatt ttttgacttc cataaaaacta ataactaagc ccataaaatta cgctggaaaga 840
 ggtcattgtat cttcatcgtc tatacgattt ctaactattt tctggacatc ttagttactg 900
 cttcagcttt ggttaaggatc ctctaaagct gtctctattt gatacattttt gccgtctggc 960
 ttaatacaga acgtggaagc cgatgttgta ttaacgacgt tggtaacat ggagctattt 1020
 cttctacttg aaatttgacc atccattatt tgattcttga gacatgaagt tgagaaatata 1080
 gagttcgittt gagatttagcc ataaatcgca tttctcttaac agtttggttct actgggtacg 1140
 gtatttagttt ccccttgat atagcacaat gcaaattgtg tagttaacta ctttggtttg 1200
 atcttctgtt ttgtttgtt tattgcaacg ttaggagttt gaaatatcct taaaatctag 1260
 ttggatttagc atagtttaatt gtgaaatatg tagtggtgcc tgagaatggt ctggattttg 1320
 aagtcttgct tcttctggaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
 aaaa 1384

<210> 36

<211> 251

<212> PRT

<213> Catalpa speciosa

<400> 36

Ala Arg Gly Arg Phe Leu Ser Arg Ile Leu Leu Phe Val Phe Gly Phe
 1 5 10 15

Tyr Trp Ile Gly Glu Thr Ser Lys Gly Ile Glu Val Asp Gly Gln Gly
 20 25 30

Asn Asn Glu Ser Ala Ser Arg Asn Arg Ser Glu Glu Val Glu Gly Pro
 35 40 45
 Gly Ala Ile Val Ser Asn His Ile Ser Tyr Ile Asp Ile Leu Tyr His
 50 55 60
Met Ser Ser Ser Phe Pro Ser Phe Val Ser Lys Arg Ser Val Ala Lys
 65 70 75 80
 Leu Pro Leu Val Gly Leu Val Ser Lys Cys Leu Gly Cys Val Tyr Val
 85 90 95
 Gln Arg Glu Leu Lys Ser Ser Asp Phe Lys Gly Val Ser Gly Val Val
 100 105 110
 Thr Glu Arg Ile Gln Glu Ala His Gln Asn Lys Phe Ala Pro Lys Met
 115 120 125
 Ile Ile Phe Pro Glu Gly Thr Thr Asn Gly Asp Phe Leu Leu Pro
 130 135 140
 Phe Lys Thr Gly Ala Phe Leu Ala Lys Ala Pro Val Leu Pro Val Ile
 145 150 155 160
 Leu Arg Tyr Ser Tyr Gln Arg Phe Ser Pro Ala Trp Asp Ser Ile Ser
 165 170 175
 Gly Ala Arg His Val Ile Leu Leu Leu Cys Gln Phe Val Asn Tyr Ile
 180 185 190
 Glu Val Thr His Leu Pro Val Tyr His Pro Ser Glu Gln Glu Lys Glu
 195 200 205
 Asp Pro Lys Leu Phe Ala Glu Asn Val Arg Leu Leu Met Ala Arg Glu
 210 215 220
 Gly Asn Leu Ile Leu Ser Asp Ile Gly Leu Ala Glu Lys Arg Val Tyr
 225 230 235 240
 His Ala Ala Leu Asn Gly Leu Leu Cys Gln Arg
 245 250

<210> 37
 <211> 1042
 <212> DNA
 <213> Triticum aestivum

<400> 37
 gcacgagcag gggttgagga gggaggccgt gctgcgtgct gcccgcgtgt tgcgcgggc 60
 aatgctgttc gtgttccgggt tctactggat ccccggtgtcc gatcgaagct tccccaaatgc 120
 cgaggatgta cctaaagatc actatgaaga actggaaaga ccagggcga ttgttatctaa 180
 tcatgtgtca tatgtggaca ttctttatca tatgtcagct tcttctccga gttttgttgc 240
 taagaactca gtgtccaagt tgccgttgat tggtctcata agcaaatgtc ttgggtgcatt 300
 ttttgttcaa cgagaatcca aatgttcaga ttctaaaggt gtctcagggtg ctgttaactga 360
 aaggtccat gaggttccac aagacgagaa ttcccctatg atcttactct ttccctgaggg 420
 tactactacg aatggggatt accttctccc atttaagaca ggagccttcc ttgcaaggc 480
 accattgcaa cctgttaattt tgagatatcc ttacaggaga tttagtccag cctgggactc 540
 catggatggg gcacgtcatg tgttttgtct cctctgtcaa ttgcaaaatt acatagaggt 600
 ggttcgcttg cctgtataact atccctctga gcaagaaaag caggatccta gagtctatgc 660
 caacaacgtc agaaaattgc ttgcgactga ggttaattt gttctgtcta atcttggct 720

ggctgaaaag cgtgtgtatc atgcggcaact taatggtaat agtccctcgta ctctgcata 780
 gaaagatgtatc tgaaaggccct tgcatacact tctgtacact atctgttgag gtgattgtaa 840
 gaatgttatgc caaccttagc tgatcatgtg attcatgtt tctctgtttg aggagtatgt 900
 tgattgtatga aaacattata cctatttga gatgaattcc ctccttatac tacattgtat 960
 agaaaccatt aaacattata gttcaataat aatgtctggc ataattgtt tgcttggca 1020
 aaaaaaaaaa aaaaaaaaaa aa 1042

<210> 38

<211> 261

<212> PRT

<213> Triticum aestivum

<400> 38

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Gly | Leu | Arg | Arg | Glu | Ala | Val | Leu | Arg | Ala | Gly | Arg | Val | Leu | Ser |
| 1 | | | | | | | | | | | | | | | 15 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ala | Met | Leu | Phe | Val | Phe | Gly | Phe | Tyr | Trp | Ile | Pro | Val | Ser | Asp |
| | | | | | | | | | | | | | | | 30 |
| | | | 20 | | | | | 25 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ser | Phe | Pro | Asn | Ala | Glu | Asp | Val | Pro | Lys | Asp | His | Tyr | Glu | Glu |
| | | | | | | | | | | | | | | | 45 |
| | | | | 35 | | | | 40 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Glu | Arg | Pro | Gly | Ala | Ile | Val | Ser | Asn | His | Val | Ser | Tyr | Val | Asp |
| | | | | | | | | | | | | | | | 60 |
| | | | | 50 | | | 55 | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Leu | Tyr | His | Met | Ser | Ala | Ser | Ser | Pro | Ser | Phe | Val | Ala | Lys | Asn |
| | | | | | | | | | | | | | | | 80 |
| | | | | 65 | | | 70 | | | | 75 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Val | Ser | Lys | Leu | Pro | Leu | Ile | Gly | Leu | Ile | Ser | Lys | Cys | Leu | Gly |
| | | | | | | | | | | | | | | | 95 |
| | | | | | | | | 85 | | | 90 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Cys | Ile | Phe | Val | Gln | Arg | Glu | Ser | Lys | Cys | Ser | Asp | Ser | Lys | Gly | Val |
| | | | | | | | | | | | | | | | 110 |
| | | | | 100 | | | | 105 | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Gly | Ala | Val | Thr | Glu | Arg | Leu | His | Glu | Val | Ser | Gln | Asp | Glu | Asn |
| | | | | | | | | | | | | | | | 125 |
| | | | | 115 | | | 120 | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Pro | Met | Ile | Leu | Leu | Phe | Pro | Glu | Gly | Thr | Thr | Thr | Asn | Gly | Asp |
| | | | | | | | | | | | | | | | 140 |
| | | | | | | | 130 | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Leu | Leu | Pro | Phe | Lys | Thr | Gly | Ala | Phe | Leu | Ala | Arg | Ala | Pro | Leu |
| | | | | | | | | | | | | | | | 160 |
| | | | | | 145 | | 150 | | | 155 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Pro | Val | Ile | Leu | Arg | Tyr | Pro | Tyr | Arg | Arg | Phe | Ser | Pro | Ala | Trp |
| | | | | | | | | | | | | | | | 175 |
| | | | | | | | 165 | | | 170 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ser | Met | Asp | Gly | Ala | Arg | His | Val | Phe | Leu | Leu | Leu | Cys | Gln | Phe |
| | | | | | | | | | | | | | | | 190 |
| | | | | 180 | | | 185 | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Asn | Tyr | Ile | Glu | Val | Val | Arg | Leu | Pro | Val | Tyr | Tyr | Pro | Ser | Glu |
| | | | | | | | | | | | | | | | 205 |
| | | | | | 195 | | 200 | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Glu | Lys | Gln | Asp | Pro | Arg | Val | Tyr | Ala | Asn | Asn | Val | Arg | Lys | Leu |
| | | | | | | | | | | | | | | | 220 |
| | | | | | 210 | | 215 | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ala | Thr | Glu | Gly | Asn | Leu | Val | Leu | Ser | Asn | Leu | Gly | Leu | Ala | Glu |
| | | | | | | | | | | | | | | | 240 |
| | | | | | 225 | | 230 | | 235 | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Lys | Arg | Val | Tyr | His | Ala | Ala | Leu | Asn | Gly | Asn | Ser | Pro | Arg | Ala | Leu |
| | | | | | | | | | | | | | | | 255 |
| | | | | | | | 245 | | 250 | | | | | | |

His Gln Lys Asp Asp
260

<210> 39
<211> 1459

<212> DNA

<213> Zea mays

<220>

<221> unsure
<222> (203)

<400> 39

| | | | | | | |
|--------------|-------------|-------------|--------------|-------------|--------------|------|
| gtttccaatc | atatctcgta | catagaaccc | atattcttct | tctatgaatt | gttcccaacc | 60 |
| attgtttcggt | cagagtctca | tgatgcccta | ccattttgttgc | gaacaatttat | tcgagcgatg | 120 |
| cagggttatata | atgttgacag | attctcacca | gttctcgga | aggctgctgt | aatatggaaata | 180 |
| aagagaaaagg | cagcttgccaa | tancttcccg | cgggtccctgt | tattccctga | aggcaccaca | 240 |
| acaaatggga | gattcctgtat | ttcggttccaa | catgggtcggt | tcataccctgg | ctaccctgtt | 300 |
| caacctgttg | ttgtccattha | tccacatgtg | cactttgatc | aatcatgggg | aaatatatcg | 360 |
| ttattaaagc | tcatgttcaa | gatgttcaca | cagtttcata | atttcatggaa | ggttagagtac | 420 |
| cttcctgttg | tctaccctcc | tgagatcaag | caagagaatg | cccttcattt | tgcagaggat | 480 |
| accagctatg | ctatggcaca | tgccctgaat | gccttgcgcga | cttattatttc | atggcgattc | 540 |
| tatgattatg | gcacgagcag | tagaagctgg | aaaggtgaac | tgctcaaatt | atatggtaga | 600 |
| aatggcttgg | gttaaagatg | tttacggtat | aagcacagca | gaagtgtatgg | aactatggaa | 660 |
| acatttcctg | gctatgaatc | cagataaacga | tggacgtgtg | aaagctgaag | atttctggc | 720 |
| tcattttgggt | ctggattgca | gtcctctgtg | caagaagata | tttcaactatt | tgcattttaga | 780 |
| cattaagggg | ttgattacgt | tccgtcagtt | cttgggttggg | tgcgcgcacc | tgaggaagca | 840 |
| accactgttc | cagggttcct | gcgagaccgc | cttggagaag | tgcgggggtc | ctgaaacgtc | 900 |
| tgagatctcc | agggcacagc | tagtgcattc | cttgcggta | agcatggtgc | cacccctctga | 960 |
| tgataagatg | ctggagctgt | tcaagacgat | cgatgttagat | ggcgcacgaga | agatcagcag | 1020 |
| ggacgacttc | atggcgtgtc | ttgggagggtt | cccgttctg | atcgcttct | ttgctgccct | 1080 |
| gatcaatggg | gaagtgtaca | tgcagatagt | ctgaatgaat | gcctgaggca | aagcgatgcc | 1140 |
| gcgtaaaagg | ctggagctgc | cagtgcagg | cgtaggcagg | ggatccctcc | gtttatgcaa | 1200 |
| tgtggatacc | caccgggtgc | tcctccactt | tgagacccaa | gcaactgttag | tattgggtat | 1260 |
| tgggttgcat | caagtggctg | accagtgtag | tgcgtcgtt | ttgttttagtt | gcttcgttgc | 1320 |
| aattattatt | ggccatttac | cgaatctgtt | gagatacgcg | ctgactagt | agattgtcga | 1380 |
| tggaactcag | aacgcaaata | gaaagcatct | gtaatctgaa | ctaactgaga | aaacatttaa | 1440 |
| aaaaaaaaaaaa | aaaaaaaaaa | | | | | 1459 |

<210> 40

<211> 204

<212> PRT

<213> Zea mays

<220>

<221> UNSURE
<222> (68)

<400> 40

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Ser | Asn | His | Ile | Ser | Tyr | Ile | Glu | Pro | Ile | Phe | Phe | Phe | Tyr | Glu |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Phe | Pro | Thr | Ile | Val | Ser | Ser | Glu | Ser | His | Asp | Ala | Leu | Pro | Phe |
| | | | | | 20 | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Gly | Thr | Ile | Ile | Arg | Ala | Met | Gln | Val | Ile | Tyr | Val | Asp | Arg | Phe |
| | | | | | | | 35 | | 40 | | | 45 | | | |

Ser Pro Ala Ser Arg Lys Ala Ala Val Asn Glu Ile Lys Arg Lys Ala
 50 55 60

Ala Cys Asn Xaa Phe Pro Arg Val Leu Leu Phe Pro Glu Gly Thr Thr
 65 70 75 80

Thr Asn Gly Arg Phe Leu Ile Ser Phe Gln His Gly Ala Phe Ile Pro
 85 90 95

Gly Tyr Pro Val Gln Pro Val Val Val His Tyr Pro His Val His Phe
 100 105 110

Asp Gln Ser Trp Gly Asn Ile Ser Leu Leu Lys Leu Met Phe Lys Met
 115 120 125

Phe Thr Gln Phe His Asn Phe Met Glu Val Glu Tyr Leu Pro Val Val
 130 135 140

Tyr Pro Pro Glu Ile Lys Gln Glu Asn Ala Leu His Phe Ala Glu Asp
 145 150 155 160

Thr Ser Tyr Ala Met Ala Arg Ala Leu Asn Ala Leu Pro Thr Tyr Tyr
 165 170 175

Ser Trp Arg Phe Tyr Asp Tyr Gly Thr Ser Ser Arg Ser Trp Lys Gly
 180 185 190

Glu Leu Leu Lys Leu Tyr Gly Arg Asn Gly Leu Gly
 195 200

<210> 41

<211> 2115

<212> DNA

<213> Oryza sativa

<400> 41

gcacgagggtt ctaaccggcc tcctctcgcc tgcctccgc caccatggc ttctcgaaac 60
 cctagccccg cctccctctc cacggcgctc ctctccgact ccatctcgcc cacgcccacc 120
 accaacggcc acggggca ccataaccac gacgacgacg acgaggaggc gccaacggtg 180
 tgcggcgccg atggcgagg agggggggac ccgttcgctt tcctatcgga ggatcgccg 240
 gcgttgtgtt cgccgcgggg ggttcccccg gccgaccctg tccgcaacgg gacgccccgg 300
 tggtgccgggg cgtacgagct cgtgaggggcg ctctgtgcg cgccgggtggc ggcggcgagg 360
 ctgggtctgt tcgggcttc catcgccgt gggtacgccc ccacgtgggt ggcgtccgc 420
 gggtggtcg acgtgcggga gcggccggcg caggaggcg ccggggccat gccggcgtgg 480
 cggcccccgc tcatgtggat cacgcggatc tccgcgcgt gcattctt ctccttcgga 540
 taccatttggta taaggagaa aggaaaaccc ggccttagag agcttgcacc tatagttgtc 600
 tcaaatacat tatcatacat agaaccata tacttcttct atgagctgtt cccgacaatc 660
 gtttcttcag attctcatga ttccatacca tttgttgaa caattatccg agcaatgcag 720
 gtttatatatg ttgacagatt ctcgcgcgt tcaaggaagt ctgtgtaaa tggaaataaaag 780
 gatgtgattt cagagaaagg cggcttgcaa tagcttccca cgtgtcttgc tattcccgaa 840
 aggcacgaca acaaatacgaa gatttctgat ttctttccaa catggtgcat tcataacctgg 900
 ctaccctgtt caacctgttta ttgtgcgcta tccacatgtg cactttgatc aatcatgggg 960
 aaatatatca ttagggaaagc tcatgttcaa gatgtttacc cagttcaca atttcatggaa 1020
 ggttagagtac ctccctgttgc tttaccacc tgagatcaag caagagaatg cccttcattt 1080
 tgcagagaac actagctatg ctagggcaca tgcacttaat gttattccaa cctcttattc 1140
 atatggggat tcaatgtatca tggctcgagc agtggaaatg gaaaaagggtga actgctcaaa 1200
 ttatatggtg gagatggctt gggtaaaaga aacatatggt gtgagcacat cagaagcaat 1260
 ggcactcttg gaagactttt tggatgatgag cccagacaag gacggacgtg tgaatgcgca 1320
 agattttgg gctcattttg gccttaatttgc caccctctt tgcaagaaga tatttcagta 1380
 cttcgattti gaagccaagg aatccatcac attccgtcag ttcttgattt gatgtgcgca 1440

cctcaggaag cagccatcg ttcaaggacgc ctgcgaaacc gcgttgaga ggtgttagaa 1500
tccccctaaca tctcacatcg gcagggagca gctcgccat gtccctgcgg caagcatgct 1560
tgagctgatg accgataatg ggatgatgaa gctgttcaag acgttggacg tcgacgatga 1620
cgacggaatc agcaaggatg acctgatggc atcccttagg aagctcccct tcatgatcgc 1680
gctttcgcg ggcggatca acgggaaagt ctacatcgag atagtttgat cgactggatt 1740
gatgcaggg gagagaaaaa atggtggatg ggagtttta acgcgggtggg agacgacaga 1800
cctccgtctg ttttagagg gatggttcc aaccgctca ccgtccatgt agctttctca 1860
ggcgtgttgg actaaagtgg ctaaccggta tagtgcgcaa ttttggcca tatcgtaaaa 1920
atatatattt atatccatag aaaagctgtc gcgtgatggc acgctggatt gtgcaatgtg 1980
gatatgatac tgtacaacat tggtccaact gggcgtgcac atagaaaactc ttttttgggt 2040
ttggtttgggt ttggctaact ggatggatga ttacaaactc ctttttggct aaaaaaaaaa 2100
aaaaaaaaaaa aaaaaa 2115

<210> 42
<211> 255
<212> PRT
<213> Oryza sativa

<400> 42
Met Ala Ser Arg Asn Pro Ser Pro Ala Ser Leu Ser Thr Pro Leu Leu
1 5 10 15

Ser Asp Ser Ile Ser Pro Thr Pro Thr Asn Gly His Ala Gly His
20 25 30

His Asn His Asp Asp Asp Glu Glu Ser Pro Thr Val Cys Gly Gly
35 40 45

Asp Gly Gly Gly Gly Asp Pro Phe Ala Phe Leu Ser Glu Asp Arg
50 55 60

Pro Ala Trp Trp Ser Pro Arg Gly Val Ser Pro Ala Asp Pro Phe Arg
65 70 75 80

Asn Gly Thr Pro Gly Trp Cys Gly Ala Tyr Glu Leu Val Arg Ala Leu
85 90 95

Val Cys Ala Pro Val Ala Ala Arg Leu Val Leu Phe Gly Leu Ser
100 105 110

Ile Ala Val Gly Tyr Ala Ala Thr Trp Val Ala Leu Arg Gly Trp Val
115 120 125

Asp Val Arg Glu Arg Ala Ala Gln Glu Gly Ala Gly Pro Met Pro Ala
130 135 140

Trp Arg Arg Arg Leu Met Trp Ile Thr Arg Ile Ser Ala Arg Cys Ile
145 150 155 160

Leu Phe Ser Phe Gly Tyr His Trp Ile Arg Arg Lys Gly Lys Pro Ala
165 170 175

Pro Arg Glu Leu Ala Pro Ile Val Val Ser Asn His Val Ser Tyr Ile
180 185 190

Glu Pro Ile Tyr Phe Phe Tyr Glu Leu Phe Pro Thr Ile Val Ser Ser
195 200 205

Asp Ser His Asp Ser Ile Pro Phe Val Gly Thr Ile Ile Arg Ala Met
210 215 220

Gln Val Ile Tyr Val Asp Arg Phe Ser Pro Ala Ser Arg Lys Ser Ala
 225 230 235 240

Val Asn Glu Ile Lys Asp Val Ile Ser Glu Lys Gly Gly Leu Gln
 245 250 255

<210> 43

<211> 2041

<212> DNA

<213> Glycine max

<400> 43

gcacgaggcg acgacgacga cttctccgtg ccgccaccgt ccaccctgga cccgttccgc 60
 aaccgcacgc cggcgatcga gggctctac gagtgggcca agacggcgct gtgcctgccc 120
 ctggcgccgc tgccgctcgc gctgttcggg ctctgcctcg cggtggtta cgtggcgacg 180
 aaggtggcgc tggcagggtg gaaggacaag gagaatccca tgcccaagtg gaggtgttagg 240
 gttatgtgga tcacgcgcct gtgcgccaga tgtattctct tctcccttgg ctatcagtgg 300
 ataaaacgga aaggaaaaacc tgccaccaagg gaaattgctc caataattgt atctaaccat 360
 gtttcttata ttgagccat cttctatttc tatgaattat ttcttaccat tggcggcagct 420
 gagtctcatg actccatacc ttttgttggc accattatta gagcaatgca ggtcatatat 480
 gttaacagat tcttaccatc atcaaggaag caggctgtt gggaaataaaa gaaatctgct 540
 ttcaaggaac tgaataacag agaaggccct cttgtgataa atttcctcga gtactattat 600
 ttcccgaggg aacaacaact aatggcgagga accttatctc cttccaactt ggtgcattta 660
 tccctggata cccaatccag cctgtaatta tacgctatcc tcatgtacac tttgaccaat 720
 cctggggtaa tggttcttg ggaaagctt tggtcagaat gttcactcaa ttccacaact 780
 ttttgaggt agaatatctt cctgtcattt atccccttgg tggataaggaa actgctgtac 840
 attttcggga gaggacttagc cgtgctatcg caactgcact aaatgctgtc cagacaggac 900
 attcttatgg agacataatg cttcatatga aagcacaaga agcaaaacag gagaacccct 960
 caagtttat ggttgaardt accaagggtgg aatcattatt tcataatcagc agcacgaaag 1020
 ctgtggactt tctggataaa ttcttggcca tgaatccctga tcccaactt cgtgttcaat 1080
 atcatgactt cttgagggtt ttaagactt aggcttgcctt actatctgca aagatatttt 1140
 cattcattga tggggagaag agtgggacaa ttacgttccag acagttctt tttggatctg 1200
 cccatgttat gtcccaacctt ggggtcgatc aaaccttga agaaggctt gctggctgtg 1260
 gcgggtcagt aaagacctat gttgttgaac aagagttacg agatttcattt caacctgcta 1320
 tcctcaattt gagtggaggat gaggtccatg agttttttt gttatttgcac aatgataatg 1380
 atggaaagaat tgacaagaat gactttctt catgccttag aagaaatctt cttctcatag 1440
 cattttttac acctcagcca cagcaaaaag aatttgaagg taatggagtg atagaaatag 1500
 tggatggat ggatttcaca ttctggactt ttgtggacta caaagaaaag aaatgggttag 1560
 ggattccctgg ggaatacata cagtagatgg tgcagtggcc tcattttttt ttttttttcc 1620
 ttttctcttt taattttttt acctgtctt gattaattac tcgtaaagca taactattt 1680
 gtgaagatct gtgccatcca tcctgttca ttgtatgttt ttgttagct aggtcagttt 1740
 tgcacagctt gatgtcagtt acctggatgt tggatcaca ccgatccac atttgagttt 1800
 tggttcaggg accatgctga catttaggtt ccatgtgggt catgtaaagt ttgaaccaac 1860
 gtgtcaattt gtaacaaaca ttataactgt atttttttc aaagatgtga acatgaagaa 1920
 agtaatgtaa ttatggaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaactcgag 1980
 ggggggccccg gttgttttcg aggtcgacgt gctcgataag attgtatcca caccgagcgc 2040
 g 2041

<210> 44

<211> 228

<212> PRT

<213> Glycine max

<400> 44

Ala Arg Gly Asp Asp Asp Asp Phe Ser Val Pro Pro Pro Ser Thr Leu
 1 5 10 15

Asp Pro Phe Arg Asn Arg Thr Pro Ala Ile Glu Gly Leu Tyr Glu Trp
 20 25 30

Ala Lys Thr Ala Leu Cys Leu Pro Leu Ala Ala Leu Arg Leu Ala Leu
 35 40 45

Phe Gly Leu Cys Leu Ala Val Gly Tyr Val Ala Thr Lys Val Ala Leu
 50 55 60

Ala Gly Trp Lys Asp Lys Glu Asn Pro Met Pro Lys Trp Arg Cys Arg
 65 70 75 80

Val Met Trp Ile Thr Arg Leu Cys Ala Arg Cys Ile Leu Phe Ser Phe
 85 90 95

Gly Tyr Gln Trp Ile Lys Arg Lys Gly Lys Pro Ala Pro Arg Glu Ile
 100 105 110

Ala Pro Ile Ile Val Ser Asn His Val Ser Tyr Ile Glu Pro Ile Phe
 115 120 125

Tyr Phe Tyr Glu Leu Phe Pro Thr Ile Val Ala Ala Glu Ser His Asp
 130 135 140

Ser Ile Pro Phe Val Gly Thr Ile Ile Arg Ala Met Gln Val Ile Tyr
 145 150 155 160

Val Asn Arg Phe Leu Pro Ser Ser Arg Lys Gln Ala Val Arg Glu Ile
 165 170 175

Lys Lys Ser Ala Phe Lys Glu Leu Asn Asn Arg Glu Gly Pro Leu Val
 180 185 190

Ile Asn Phe Leu Glu Tyr Tyr Phe Pro Arg Glu Gln Gln Leu Met
 195 200 205

Ala Gly Thr Leu Ser Pro Ser Asn Leu Val His Leu Ser Leu Asp Thr
 210 215 220

Gln Ser Ser Leu
 225

<210> 45

<211> 1502

<212> DNA

<213> Zea mays

<400> 45

| | | | | | | |
|-------------|-------------|------------|-------------|-------------|------------|-----|
| gcacagggtc | gtcctcacca | tgccgatccg | gcgtcagcgc | tagggtagg | gtctccctcg | 60 |
| cgccttatac | gccatggctc | ctaacaagc | cgctagcattc | accaccccgt | ccgagccgga | 120 |
| gagcgtggc | ggcagtgaga | tgagcagcga | agacatggcc | gcccgcagtc | cgctcccttc | 180 |
| gtcgtccctc | ccctccccctt | ccccctccgc | agccccgggt | ctggagagca | tagaggaact | 240 |
| ggaccggaag | tacgcaccgt | acgcgcggcg | ggacgcgtac | ggaccgatgg | ggctcgcccc | 300 |
| cgtgacgcga | gcggaggctg | cgccgctggc | gtttgcccg | gtctgtctgg | tcccgcctcg | 360 |
| tgtcggtggca | ggtgttctcg | tactcggtgt | ctactacctc | gtgtgcgcgc | tgtgcacgct | 420 |
| gcgggtggag | gaggaccggg | agggcggcga | aggggatggg | tacgcgcgg | tggacgggtg | 480 |
| gaggcggcg | ggggctgtgc | ggtgccggcg | cgcaactcgct | cgcccatgt | tgtttgtctt | 540 |
| cgggttctat | tggatccgag | agtacgacag | ccgccttccc | aatgtctgagg | atggccatgt | 600 |
| ggaccagtct | aaagaaaatcg | aaaggcctgg | ggcaattgt | tctaattatgt | tatcttatgt | 660 |
| ggtatattctt | tatcacatgt | cagcctcttt | tcctagttt | gttgctaaaga | gatcagtggc | 720 |
| tagattgcct | ctagttggtc | tcataagcaa | atgtcttgg | tgcattttt | ttcagcggga | 780 |
| gtcgaaaaca | ccagatttca | aagggtttc | aggtgctgt | tctgaaagaa | tccatcgtgc | 840 |

tcataaacag aaaaatgcac caatgatgct actctccct gagggcacaa ctacaatgg 900
 ggatttatctc cttccattca aaacagggtgc ttttcttgca aaggcaccag ttcaaccagt 960
 catttgaga tatkcttaca aaagatttaa tgtagcatgg gatccatgt caggggcacg 1020
 tcatgtatctt ctgctgctct gtcaatttgt aaattaccta gaggtggtcc gcttaccagt 1080
 ttactatccct tctgagcaag aaaaggatga tcctaagctc tatgcaaaca atgtacggaa 1140
 actgatggca gtggagggaa acttgattct ttcagacctt gggctggcg 1200
 gtaccatgcc gcactgaatg gtaatagtct agctcggtct ttacatcaga aagatgattg 1260
 aaatgccatg ctatcggtct tccataatac tggcttgctt gtaactgtgt gcttgcttgt 1320
 gcatcgcatg ggtttagagg aatgtcgta atataactatc cgccataaaat ctgtaaagta 1380
 atttaccaac tgtcatagtt cagtaattat gttggttata ctcctacatg gttgggcac 1440
 cgcacatttgc atcctgtggt caatccatgt gagccttt tactaaaaaa aaaaaaaaaa 1500
 aa 1502

<210> 46

<211> 395

<212> PRT

<213> Zea mays

<400> 46

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Pro | Asn | Glu | Ala | Ala | Ser | Ile | Thr | Thr | Pro | Ser | Glu | Pro | Glu |
| 1 | | | | | | | | | | | | | | 10 | 15 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Ser | Val | Gly | Gly | Ser | Glu | Met | Ser | Ser | Glu | Asp | Met | Ala | Ala | Ala | Ser | |
| | | | | | | | | | | | | | | 20 | 25 | 30 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Leu | Leu | Ser | Ser | Ser | Ser | Pro | Ser | Pro | Ser | Pro | Ser | Ala | Ala | Ala | Pro |
| | | | | | | | | | | | | | | 35 | 40 | 45 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Val | Leu | Glu | Ser | Ile | Glu | Glu | Leu | Asp | Arg | Lys | Tyr | Ala | Pro | Tyr | Ala | |
| | | | | | | | | | | | | | | 50 | 55 | 60 |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----|
| Arg | Arg | Asp | Ala | Tyr | Gly | Pro | Met | Gly | Leu | Gly | Pro | Val | Ser | Ala | Ala | | |
| | | | | | | | | | | | | | | 65 | 70 | 75 | 80 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|
| Glu | Ala | Ala | Arg | Leu | Ala | Phe | Ala | Ala | Val | Val | Leu | Val | Pro | Leu | Arg | |
| | | | | | | | | | | | | | | 85 | 90 | 95 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Val | Ala | Gly | Val | Leu | Val | Leu | Val | Val | Tyr | Tyr | Leu | Val | Cys | Arg | |
| | | | | | | | | | | | | | | 100 | 105 | 110 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Cys | Thr | Leu | Arg | Val | Glu | Glu | Asp | Arg | Glu | Gly | Glu | Gly | Asp | | |
| | | | | | | | | | | | | | | 115 | 120 | 125 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Tyr | Ala | Arg | Leu | Asp | Gly | Trp | Arg | Arg | Ala | Gly | Ala | Val | Arg | Cys | |
| | | | | | | | | | | | | | | 130 | 135 | 140 |

| | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Arg | Ala | Leu | Ala | Arg | Ala | Met | Ieu | Phe | Val | Phe | Gly | Phe | Tyr | Trp | | |
| | | | | | | | | | | | | | | 145 | 150 | 155 | 160 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Arg | Glu | Tyr | Asp | Ser | Arg | Leu | Pro | Asn | Ala | Glu | Asp | Gly | His | Val | |
| | | | | | | | | | | | | | | 165 | 170 | 175 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Gln | Ser | Lys | Glu | Ile | Glu | Arg | Pro | Gly | Ala | Ile | Val | Ser | Asn | His | |
| | | | | | | | | | | | | | | 180 | 185 | 190 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Ser | Tyr | Val | Asp | Ile | Leu | Tyr | His | Met | Ser | Ala | Ser | Phe | Pro | Ser | |
| | | | | | | | | | | | | | | 195 | 200 | 205 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Val | Ala | Lys | Arg | Ser | Val | Ala | Arg | Leu | Pro | Leu | Val | Gly | Leu | Ile | |
| | | | | | | | | | | | | | | 210 | 215 | 220 |

Ser Lys Cys Leu Gly Cys Ile Phe Val Gln Arg Glu Ser Lys Thr Pro
225 230 235 240

Asp Phe Lys Gly Val Ser Gly Ala Val Ser Glu Arg Ile His Arg Ala
245 250 255

His Gln Gln Lys Asn Ala Pro Met Met Leu Leu Phe Pro Glu Gly Thr
260 265 270

Thr Thr Asn Gly Asp Tyr Leu Leu Pro Phe Lys Thr Gly Ala Phe Leu
275 280 285

Ala Lys Ala Pro Val Gln Pro Val Ile Leu Arg Tyr Pro Tyr Lys Arg
290 295 300

Phe Asn Ala Ala Trp Asp Ser Met Ser Gly Ala Arg His Val Phe Leu
305 310 315 320

Leu Leu Cys Gln Phe Val Asn Tyr Leu Glu Val Val Arg Leu Pro Val
325 330 335

Tyr Tyr Pro Ser Glu Gln Glu Lys Asp Asp Pro Lys Leu Tyr Ala Asn
340 345 350

Asn Val Arg Lys Leu Met Ala Val Glu Gly Asn Leu Ile Leu Ser Asp
355 360 365

Leu Gly Leu Ala Glu Lys Arg Val Tyr His Ala Ala Leu Asn Gly Asn
370 375 380

Ser Leu Ala Arg Ala Leu His Gln Lys Asp Asp
385 390 395

<210> 47

<211> 1555

<212> DNA

<213> Oryza sativa

<400> 47

gcacgagggt taaaaccacgt ctcgtcgcca tctcctcatg cctaccact gctagggttt 60
gcccttaagc ccccccacccct ctccggccatg gctctccctc tccacgacgc caccacctcc 120
ccctccgacc cgcacgacccct cggcgccggc ggcgaggagg aggaggagag gctcgccctcg 180
aagccgctgc tctcgcccccc gtccacctat cttccgcgg ggacggagga gggcgctcgag 240
gagctggagc tcgaccggag gtacgcgccc tacgcgagggc gggacgcgtta cggggcgatg 300
ggccggggcc ccctgggcgc ggcggggcg gggcggctgg cggtggcgc cccgtgtc 360
ttccccgtcc ggctcgccgc gggcgtgctc gtgctcgctcg cctactacct cgtgtgccgc 420
gtgtgcacgc tgcgtgtgga ggaggaggag cgcgagggtg gcgggtggcgg cgcggctgga 480
gaagtggagg gggacgggta cgcgcggctc gaggggtgaa ggcgtgaggg cgtcgctcg 540
tgcggccgcg cgcgtcgccgc cgcgcgtctg ttgcgtcttcg gtttctactg gatccgcgag 600
tacgactgcc gttccctga tgctgaggat gaggcatcagg aacagtccaa agaattggga 660
agaccagggg cagtagtatc taatcatgta tcttatgtgg atattcttta ccacatgtca 720
tcttccttcc caagctttgt tgccaaagaga tcagtgccca gattgccat gtttgtctc 780
ataagcaaat gtcttgatg cattttggat cagcggaaat ctaaaacctc agattcaaa 840
ggcggttcag gtgtgtgac tgagagaatc caacgggcgc atcaacagaa gaattctcca 900
atgatgctac ttttccctga aggcacaact acaaattggtg attatctctt cccttcaag 960
acaggagcat ttcttgcaaa agcaccagt aagccagtca tttaagata tccttacaag 1020
agattttagtc cagcatggga ttgcgtgtct ggggctcgcc atgtatttct gtcctttgt 1080
caatttgtaa ataaccttga ggtgatccat ttgcctgtgtt attacccatc tgagcaagag 1140
aaggaagatc ctaagctgta cgcaaataat gtacggaaat tgcgtgtt gggggaaac 1200

ttgattcttt ctgatcttgg gctagcagag aagcgtgtgt accatgcggc attgaatgg 1260
 aataatagtc tacctcggtc tttacatcg aaagatgatt gaaaatgcctt gccatcgcc 1320
 ttctgtatac tgatgcttag tgacttgctt gtaatatgag tacaaggttcc tggtgttgc 1380
 tgattcctca tggtgagagg agctatgtt atatcctccc agtaaaactgt aaaattattt 1440
 gccccatagtg tggttcagta atcatgtcag ttatacatga ttacattcac atgtctggga 1500
 cacacccac catgcaatcc atcgatgtga gctttataaa aaaaaaaaaa aaaaa 1555

<210> 48
<211> 404
<212> PRT
<213> Oryza sativa

<400> 48
Met Ala Leu Pro Leu His Asp Ala Thr Thr Ser Pro Ser Asp Pro Asp
1 5 10 15

Asp Leu Gly Gly Gly Glu Glu Glu Glu Arg Leu Ala Ser Lys
20 25 30

Pro Leu Leu Ser Ser Pro Ser Thr Tyr Pro Ser Ala Gly Thr Glu Glu
35 40 45

Gly Val Glu Glu Leu Glu Leu Asp Arg Arg Tyr Ala Pro Tyr Ala Arg
50 55 60

Arg Asp Ala Tyr Gly Ala Met Gly Arg Gly Pro Leu Gly Ala Ala Gly
65 70 75 80

Ala Gly Arg Leu Ala Val Gly Ala Ala Val Leu Phe Pro Leu Arg Leu
85 90 95

Ala Ala Gly Val Leu Val Leu Val Ala Tyr Tyr Leu Val Cys Arg Val
100 105 110

Cys Thr Leu Arg Val Glu Glu Glu Arg Glu Gly Gly Gly Gly
115 120 125

Ala Ala Gly Glu Val Glu Gly Asp Gly Tyr Ala Arg Leu Glu Gly Trp
130 135 140

Arg Arg Glu Gly Val Val Arg Cys Gly Arg Ala Leu Ala Arg Ala Met
145 150 155 160

Leu Phe Val Phe Gly Phe Tyr Trp Ile Arg Glu Tyr Asp Cys Arg Phe
165 170 175

Pro Asp Ala Glu Asp Glu His Gln Glu Gln Ser Lys Glu Leu Gly Arg
180 185 190

Pro Gly Ala Val Val Ser Asn His Val Ser Tyr Val Asp Ile Leu Tyr
195 200 205

His Met Ser Ser Ser Phe Pro Ser Phe Val Ala Lys Arg Ser Val Ala
210 215 220

Arg Leu Pro Met Val Gly Leu Ile Ser Lys Cys Leu Gly Cys Ile Phe
225 230 235 240

Val Gln Arg Glu Ser Lys Thr Ser Asp Phe Lys Gly Val Ser Gly Ala
245 250 255

Val Thr Glu Arg Ile Gln Arg Ala His Gln Gln Lys Asn Ser Pro Met
 260 265 270

Met Leu Leu Phe Pro Glu Gly Thr Thr Thr Asn Gly Asp Tyr Leu Leu
 275 280 285

Pro Phe Lys Thr Gly Ala Phe Leu Ala Lys Ala Pro Val Lys Pro Val
 290 295 300

Ile Leu Arg Tyr Pro Tyr Lys Arg Phe Ser Pro Ala Trp Asp Ser Met
 305 310 315 320

Ser Gly Ala Arg His Val Phe Leu Leu Cys Gln Phe Val Asn Asn
 325 330 335

Leu Glu Val Ile His Leu Pro Val Tyr Tyr Pro Ser Glu Gln Glu Lys
 340 345 350

Glu Asp Pro Lys Leu Tyr Ala Asn Asn Val Arg Lys Leu Met Ala Val
 355 360 365

Glu Gly Asn Leu Ile Leu Ser Asp Leu Gly Leu Ala Glu Lys Arg Val
 370 375 380

Tyr His Ala Ala Leu Asn Gly Asn Asn Ser Leu Pro Arg Ala Leu His
 385 390 395 400

Gln Lys Asp Asp

<210> 49

<211> 1072

<212> DNA

<213> Glycine max

<400> 49

gcacgaggga agattacgt catatgagtg gtttggggag aaccgtcatt gtttcgttgt 60
 gacgcgcct ctccagagtc atgctttca ttttcggctt ttattggatc cccgaatcca 120
 actctgcctc tcaggaagac cggagttagc ctgaagagtt ggggagacct agcgtaataaa 180
 tatctaatac tttgtcatac ttggatattt ttgtatcacat gtcgtcctca ttcccaagtt 240
 ttgttgcataa gagatcgtg gctaaacttc cgctcatgg tctcatcagc aagtgccttg 300
 gtttgtgtta tggtcagccg gaatcaaagt catcgactt caagggtgtt tcagctgttg 360
 tcactgacag aattcaagaa gctcatcaga atgagtctgc tccattaatg atgttatttc 420
 cagaaggaac aaccacaaat ggaggttcc tccttccatt caagactggg gttttttgg 480
 caaaggcacc agtacttctt gtgatttaa gatatcatta ccagagattt agccccgcct 540
 gggatccat atctgggtt cgccatgtaa tatttctctt gtgtcagttt gtgaattata 600
 tggaggttat ccgagttactt gtttaccatc cctcacagca ggagatgaat gatcccaaac 660
 tatatgtctaa taatgttaga aggtttaggg ctactgaggg taatttgata ctttctgata 720
 ttgggttagc tgaaaaacga atatatcacg ctgtctcaa tggtaataat agcatgccta 780
 gtgttttgcg tcaaaaaacgc gaatgataat ttcatggccc ccgtctcaaa tgaaatgttag 840
 ttccagtcga tttttagtt caaacttagt atctgtttat gaatggacag cttgtgtgaa 900
 gggtagtata aataatgtata cattcaccta aacatctgaa tggtacttgc gtaattttct 960
 tgtaaataaac gtgaccaata atgtttaat tgctggtaa ctcaatttga ggcacacaat 1020
 tcaagatcta taagtttaac tgttttcgta tcaaaaaaaaaaaa aa 1072

<210> 50

<211> 267

<212> PRT

<213> Glycine max

<400> 50
 Thr Arg Glu Asp Tyr Ala His Met Ser Gly Leu Arg Arg Thr Val Ile
 1 5 10 15

Val Ser Cys Gly Arg Ala Leu Ser Arg Val Met Leu Phe Ile Phe Gly
 20 25 30

Phe Tyr Trp Ile Pro Glu Ser Asn Ser Ala Ser Gln Glu Asp Arg Ser
 35 40 45

Gln Pro Glu Glu Leu Gly Arg Pro Ser Val Ile Ile Ser Asn His Val
 50 55 60

Ser Tyr Leu Asp Ile Leu Tyr His Met Ser Ser Ser Phe Pro Ser Phe
 65 70 75 80

Val Ala Lys Arg Ser Val Ala Lys Leu Pro Leu Ile Gly Leu Ile Ser
 85 90 95

Lys Cys Leu Gly Cys Val Tyr Val Gln Arg Glu Ser Lys Ser Ser Asp
 100 105 110

Phe Lys Gly Val Ser Ala Val Val Thr Asp Arg Ile Gln Glu Ala His
 115 120 125

Gln Asn Glu Ser Ala Pro Leu Met Met Leu Phe Pro Glu Gly Thr Thr
 130 135 140

Thr Asn Gly Glu Phe Leu Leu Pro Phe Lys Thr Gly Gly Phe Leu Ala
 145 150 155 160

Lys Ala Pro Val Leu Pro Val Ile Leu Arg Tyr His Tyr Gln Arg Phe
 165 170 175

Ser Pro Ala Trp Asp Ser Ile Ser Gly Val Arg His Val Ile Phe Leu
 180 185 190

Leu Cys Gln Phe Val Asn Tyr Met Glu Val Ile Arg Val Pro Val Tyr
 195 200 205

His Pro Ser Gln Gln Glu Met Asn Asp Pro Lys Leu Tyr Ala Asn Asn
 210 215 220

Val Arg Arg Leu Met Ala Thr Glu Gly Asn Leu Ile Leu Ser Asp Ile
 225 230 235 240

Gly Leu Ala Glu Lys Arg Ile Tyr His Ala Ala Leu Asn Gly Asn Asn
 245 250 255

Ser Met Pro Ser Val Leu His Gln Lys Asp Glu
 260 265

<210> 51
<211> 838
<212> DNA
<213> Glycine max

<220>
 <221> unsure
 <222> (205)

<220>
 <221> unsure
 <222> (779)

<220>
 <221> unsure
 <222> (814)

<400> 51

gagagaacta gtctcagcca ttttccattt ctttccactt ttatgtttc aggtcatata 60
 tgttaacaga ttcttaccat catcaaggaa gcaggctgtt agggaaataa agagaaggc 120
 ctcttgcaat agatttcctc gagtactatt atttcccgag ggaacaacaa caaatggcag 180
 gaaccttatac tccttccaaac ttggngcatt tateccctgga tacccaatcc agcctgtata 240
 tgtacgctat cctcatgtgc actttgacca atcctggggt catgttctt tggaaagct 300
 tatgttcaga atgttcactc aatttcacaa ctttttgag gtagaatatc ttccctgtcat 360
 ttatcccctg gatgataagg aaactgtgt acattttcgg gagaggacta gccgtgtat 420
 cgcaactgca ctaaatgctg tccagacagg acattcttat ggagacataa tgcttcata 480
 gaaagcacaa gaagcaaaac aggagaaccc ctcaagttt atggttggaaa tgaccaaggt 540
 ggaatcagtg agtccctaaa agcaaatgac cttaccattt ccttttttt tctgccattt 600
 tcaagtccct tgtaaattat cttttcttt aactttttaa gtaggatatt taggttaaac 660
 ctttgaagt acatgcaaat gccacagtaa cccttgcctt atgccaatgg atgacagaca 720
 taagtgaccc agggtgtggctg cataatgttg gggccttcta atctatgggaa aatatgtant 780
 gaaaggggag aatatttaaa ttgtgatttg tggnaataag gggataatat gacataag 838

<210> 52

<211> 185

<212> PRT

<213> Glycine max

<400> 52

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Glu | Leu | Val | Ser | Ala | Ile | Phe | His | Phe | Phe | Pro | Leu | Leu | Cys | Phe |
| 1 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 10 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Val | Ile | Tyr | Val | Asn | Arg | Phe | Leu | Pro | Ser | Ser | Arg | Lys | Gln | Ala |
| 20 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 30 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Arg | Glu | Ile | Lys | Arg | Arg | Ala | Ser | Cys | Asn | Arg | Phe | Pro | Arg | Val |
| 35 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 40 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 45 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 50 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 55 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | |
|----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| 60 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

Asn Ala Val Gln Thr Gly His Ser Tyr Gly Asp Ile Met Leu His Met
 145 150 155 160

Lys Ala Gln Glu Ala Lys Gln Glu Asn Pro Ser Ser Phe Met Val Glu
 165 170 175

Met Thr Lys Val Glu Ser Val Ser Pro
 180 185

<210> 53

<211> 1632

<212> DNA

<213> Oryza sativa

<400> 53

cttctcgatccggatt cggccggcc tccgcccggc cggccggagg aggaggacga 60
 ggagagggcg ctccctcggt ggtgagcatc cagccaccc gcggccgttc ctccttc 120
 catctcgcc cccgcgaggatt ggaagtgggg gcaggccagg gcggcagggg ccatggcggt 180
 cccactcgatcc tcgtcgatcc tccccctcggt ctccttc ctccttcgc gcctcatcat 240
 caacccatc caggccgtcc tgtttcttc gataaggccg ttctcgaaga gcttgtaccg 300
 gcgatcaac aggttcttg ccgagctgt gtggcttcag ctggcttcgc ttgtggattg 360
 gtggcagga gttaagatac aactgcatgc tgatgacgaa acttacaagg caatggggaa 420
 tgagcatgca ttgtcatat caaataatcg gagcgatatac gattggctta ttgggtggat 480
 tttggcacag cgctcaggat gccttggaa tacacttgct gttatgaaga aatcatcgaa 540
 attccttcca gttattggct ggtccatgtg gtttgcagaa taccttcttt tgaaaaggag 600
 ctggccaaag gataaaaaaga cattgaaatg gggcctccaa aggttgaagg acttccccag 660
 accattttgg cttagccctt ttgttgaggg cactcgctt actccagcaa agttcttagc 720
 agctcaggag tatgctgtt cacagggtt gccagcaccc agaaatgtat tgattccacg 780
 tacaaggaa ttgttatcag ctgtactat tatgcgggat ttgttccag ctatttatga 840
 tacaacagta attattccaa aagattcacc tcaaccaaca atgctcgga ttttggaaagg 900
 gcaatctca gtggtacatg ttgcgtatgaa acgtcatgca atgagtgaga tgccaaagtc 960
 agaagacgat gtttcaaaat ggtgaaaga catcttgc gcaaaggatg cattactgga 1020
 taagcatttgc ggcacaggca ctttgcgtatgaa ggagatttgc ccaattggcc gcccagtaaa 1080
 atcatgtgt gtgactttgt ttgttgcgtatg ttccttttgc tatggcgcc tcaagcttt 1140
 cctatggact caactcctgt cgacatggaa aggagtccggg ttacggggcc ttgggctcg 1200
 actggtgacg gcggtcatgc atgttgcgtatgatc catgttgcgtatg cagtcagacg gatcgagctc 1260
 agccaaggcg gctcgaaacc gtgtcaagaa agattgaaag agatgaagat agagtctgca 1320
 gcttatcaat gggagctacc aattaattgg gtattgaaat catgtggca aaaaaatttga 1380
 gggcctaattt tttccgtat aatgcaccaaa aagggttctt acagaactga atgcctgaat 1440
 agagagattt taggagattt ggtgaaacttag caactctgatc ctctgttgc ctgtattttc 1500
 agagaatgtt tttttggca gaacaggaat tgtactactt gtatttatttgc gaacttctac 1560
 atcagtctgg atttggatcag aagaccttgcgtatc tatcagtggaa actaaaaaaa 1620
 aaaaaaaaaaa aa 1632

<210> 54

<211> 374

<212> PRT

<213> Oryza sativa

<400> 54

Met Ala Val Pro Leu Val Leu Val Val Leu Pro Leu Gly Leu Leu Phe
 1 5 10 15

Leu Leu Ser Gly Leu Ile Ile Asn Ala Ile Gln Ala Val Leu Phe Leu
 20 25 30

Ser Ile Arg Pro Phe Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg Phe
 35 40 45

Leu Ala Glu Leu Leu Trp Leu Gln Leu Val Trp Leu Val Asp Trp Trp
 50 55 60

Ala Gly Val Lys Ile Gln Leu His Ala Asp Asp Glu Thr Tyr Lys Ala
 65 70 75 80

Met Gly Asn Glu His Ala Leu Val Ile Ser Asn Asn Arg Ser Asp Ile
 85 90 95

Asp Trp Leu Ile Gly Trp Ile Leu Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110

Ser Thr Leu Ala Val Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
 115 120 125

Gly Trp Ser Met Trp Phe Ala Glu Tyr Leu Phe Leu Glu Arg Ser Trp
 130 135 140

Ala Lys Asp Glu Lys Thr Leu Lys Trp Gly Leu Gln Arg Leu Lys Asp
 145 150 155 160

Phe Pro Arg Pro Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg Phe
 165 170 175

Thr Pro Ala Lys Leu Leu Ala Ala Gin Glu Tyr Ala Val Ser Gln Gly
 180 185 190

Leu Pro Ala Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe Val
 195 200 205

Ser Ala Val Thr Ile Met Arg Asp Phe Val Pro Ala Ile Tyr Asp Thr
 210 215 220

Thr Val Ile Ile Pro Lys Asp Ser Pro Gln Pro Thr Met Leu Arg Ile
 225 230 235 240

Leu Lys Gly Gln Ser Ser Val Val His Val Arg Met Lys Arg His Ala
 245 250 255

Met Ser Glu Met Pro Lys Ser Glu Asp Asp Val Ser Lys Trp Cys Lys
 260 265 270

Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Leu Ala Thr
 275 280 285

Gly Thr Phe Asp Glu Glu Ile Arg Pro Ile Gly Arg Pro Val Lys Ser
 290 295 300

Leu Leu Val Thr Leu Phe Trp Ser Cys Leu Leu Leu Tyr Gly Ala Val
 305 310 315 320

Lys Leu Phe Leu Trp Thr Gln Leu Leu Ser Thr Trp Lys Gly Val Gly
 325 330 335

Phe Thr Gly Leu Gly Leu Ala Leu Val Thr Ala Val Met His Val Phe
 340 345 350

Ile Met Phe Ser Gln Ser Glu Arg Ser Ser Ala Lys Ala Ala Arg
 355 360 365

Asn Arg Val Lys Lys Asp
370

<210> 55
<211> 1498
<212> DNA
<213> Glycine max

<400> 55
gcacgagggtt ccgttgctg acctgaccc tcacgggttt 60
tcgttgcgtt gtgctctgt ctgctccctt gggcctggc tgggctggc tgggctggc 120
tgggcatggc tattgcagca gcggccgtgg tggtaccatt gggcctgct ttcttcgcct 180
ccggccctcct tgtaatctc attcaggcaa tatgctatgt cgtcgtaagg ccggtgtcga 240
aaagtttcta cagaaggatc aaccgggttag tagcagagct cttgtggctg gagcttgtat 300
ggcttattga ttgggtggca ggagtttaagg tccaaatatt cacagatcat gaaaccttcc 360
gtttaatggg taaagagcat gcacttgta taagcaatca cagaagtgtat attgattggc 420
ttgttggatg ggtttcagct cagcgttcag gttgtcttgg cagcactcta gctgtgtatg 480
agaaaatctc aaagtttctg ccggtcattt gctggtcaat gtggtttctt gagtatctt 540
ttctggagag aagttggcc aaggatgaaa gcacattttt gtcaggcatc cagcgactga 600
gtgatttccc tcttcccttt tggctagctc tctttgtaga aggaacgcgt tttacacagg 660
ccaaactatt agctgcttag gaatatgcca cttccactgg attgcctgtt cctagaaatg 720
ttttgattcc aagaactaaag gtttttgtt ctgcagtaag tcatatgcgc tcattttttc 780
ctgccattta tgatgttaaca gtagccatcc ctaagagtcc ccctgtctt acaatgttta 840
gactcttcaa gggacaacct tcagttgtgc atgttcatat caagaggcat ttgtatgaagg 900
aactgcccaga tacagatgag gctgttgctc aatggtgcg agatataattt gtggccaagg 960
atgctttttt agacaaacat atggctgagg gtacttttag tgatcaagag ctgcaggata 1020
ctggtcgacc aataaaagtct cttctggtag ttatatcttgc ggcgtgtctg gttgttgccg 1080
ggtctgtaaa gttcctgcaa tggctttcgat tactcttcc ctggaaagggt gttgcatttt 1140
cagcttttgg tttggcagtt gttactgcac ttatgcaaat tctgattcaa ttctcacagt 1200
cagagcgttc aaaccggcc aagatcgtgc ctgcaaaagtc aaaaaacaag gggcttgcg 1260
ttatggcg aacttaaagt tgcatttttgc tggatgagttt gactcatgtt atactcatta 1320
ttttgccttc aacatcttat catagtatgc ttcttatttca tataatgtact attatgaatg 1380
cttacgcattt cattgttttta aatttaattt ggatatccctt ttgtatttgc agtcttagggg 1440
atggccataga aaaattcaac cacctattttt attttaaaaaa aaaaaaaaaa aaaaaact 1498

<210> 56
<211> 377
<212> PRT
<213> Glycine max

<400> 56

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ile | Ala | Ala | Ala | Val | Val | Val | Pro | Leu | Gly | Leu | Leu | Phe |
| 1 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | 10 |
| | | | | | | | | | | | | | | 15 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Ala | Ser | Gly | Leu | Leu | Val | Asn | Leu | Ile | Gln | Ala | Ile | Cys | Tyr | Val |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 20 |
| | | | | | | | | | | | | | | | 25 |
| | | | | | | | | | | | | | | | 30 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Val | Arg | Pro | Val | Ser | Lys | Ser | Leu | Tyr | Arg | Arg | Ile | Asn | Arg | Val |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 35 |
| | | | | | | | | | | | | | | | 40 |
| | | | | | | | | | | | | | | | 45 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Val | Ala | Glu | Leu | Leu | Trp | Leu | Glu | Leu | Val | Trp | Leu | Ile | Asp | Trp | Trp |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 50 |
| | | | | | | | | | | | | | | | 55 |
| | | | | | | | | | | | | | | | 60 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Gly | Val | Lys | Val | Gln | Ile | Phe | Thr | Asp | His | Glu | Thr | Phe | Arg | Leu |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 65 |
| | | | | | | | | | | | | | | | 70 |
| | | | | | | | | | | | | | | | 75 |
| | | | | | | | | | | | | | | | 80 |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Lys | Glu | His | Ala | Leu | Val | Ile | Ser | Asn | His | Arg | Ser | Asp | Ile |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | 85 |
| | | | | | | | | | | | | | | | 90 |
| | | | | | | | | | | | | | | | 95 |

Asp Trp Leu Val Gly Trp Val Ser Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110
 Ser Thr Leu Ala Val Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
 115 120 125
 Gly Trp Ser Met Trp Phe Ser Glu Tyr Leu Phe Leu Glu Arg Ser Trp
 130 135 140
 Ala Lys Asp Glu Ser Thr Leu Lys Ser Gly Ile Gln Arg Leu Ser Asp
 145 150 155 160
 Phe Pro Leu Pro Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg Phe
 165 170 175
 Thr Gln Ala Lys Leu Leu Ala Ala Gln Glu Tyr Ala Thr Ser Thr Gly
 180 185 190
 Leu Pro Val Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe Val
 195 200 205
 Ser Ala Val Ser His Met Arg Ser Phe Val Pro Ala Ile Tyr Asp Val
 210 215 220
 Thr Val Ala Ile Pro Lys Ser Ser Pro Ala Pro Thr Met Leu Arg Leu
 225 230 235 240
 Phe Lys Gly Gln Pro Ser Val Val His Val His Ile Lys Arg His Leu
 245 250 255
 Met Lys Glu Leu Pro Asp Thr Asp Glu Ala Val Ala Gln Trp Cys Arg
 260 265 270
 Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Met Ala Glu
 275 280 285
 Gly Thr Phe Ser Asp Gln Glu Leu Gln Asp Thr Gly Arg Pro Ile Lys
 290 295 300
 Ser Leu Leu Val Val Ile Ser Trp Ala Cys Leu Val Val Ala Gly Ser
 305 310 315 320
 Val Lys Phe Leu Gln Trp Ser Ser Leu Leu Ser Ser Trp Lys Gly Val
 325 330 335
 Ala Phe Ser Ala Phe Gly Leu Ala Val Val Thr Ala Leu Met Gln Ile
 340 345 350
 Leu Ile Gln Phe Ser Gln Ser Glu Arg Ser Asn Pro Ala Lys Ile Val
 355 360 365
 Pro Ala Lys Ser Lys Asn Lys Gly Ser
 370 375

<210> 57
 <211> 1415
 <212> DNA
 <213> Triticum aestivum

<400> 57

| | | | | | | |
|-------------|-------------|------------|--------------|------------|-------------|------|
| gcacgaggag | aggagacgcg | gcggcggcca | tggcgattcc | cctcggtc | gtacctgtcc | 60 |
| cgctcgccct | cctcttcctc | ctctccggcc | tcgtcgtaa | cactgtccag | gccgtattgt | 120 |
| tcttgcacat | aaggccattc | tcgaagcgat | tgtaccggca | gatcaacgta | ttcctggccg | 180 |
| agttgttgt | gcttcagctg | atctggctt | tggactgggt | ggcaggtatt | aaggtacagg | 240 |
| tgtatgcgga | tccagaaaact | tggaaactaa | tgcccggaaaga | gcacgccc | ctcatatcca | 300 |
| atcatcgaa | tgacattgat | tggctgggt | gatggatttt | agcacagcgt | tcaggatgtc | 360 |
| ttggaagcgc | aatacgatata | atgaagaaat | cctcaaagg | ccttcagtt | attgggttgg | 420 |
| ccatgtggtt | tgcagaatac | ctcttttgg | agagaagctg | ggcaaaggat | aaaaaaacac | 480 |
| ttaaatcggg | tcttcaaagg | ttgaaagact | tcccagatc | attttggctt | gcccttttg | 540 |
| ttgagggtac | aagatttact | ccagaaaaac | ttttagcagc | tcaagaatat | gcagtctcac | 600 |
| agggttgac | agcgcctagg | aatgtgctga | ttccacgaac | aaaggattt | gtatcagctg | 660 |
| taagtattat | gcgtgactt | gtcccagcta | tctacgatac | aacagtgatt | attccggaaag | 720 |
| attcgctaa | accaacaatg | ctcgatattc | ttcagggaca | atcatcagtt | gttcatgtcc | 780 |
| gcataaaaacg | ccattcaatg | agtgatatgc | ctaactcgga | tgaggatgtt | tcaaaatgg | 840 |
| gcaaagatat | atttgcgtca | aaggacgcgt | tattggacaa | acatatacg | actggtactt | 900 |
| ttgatgagga | aattatacca | atggccgtc | cagtgaard | tttgatgggt | gtcctgtctt | 960 |
| ggtcatgtct | cctcctata | ggtgctcata | gattctaca | gtggacc | ctctgtcga | 1020 |
| cgtggaaagg | agtgatc | tttgctctg | gattggcaat | gttaacc | gttatgc | 1080 |
| tattcatcat | gttctcg | ccgagcgt | caagctctg | gaaagcag | aggaccg | 1140 |
| tgaagaagga | ttgatagctc | gtgtgaard | cagtctatag | gggaactg | ccaaatttatt | 1200 |
| gttcagaata | tatgttagaca | caggccat | gggtcaa | tagtatgt | ttgttgtc | 1260 |
| cggtaagagc | ttcaggaatt | ttgtgtggcg | agaactgt | gctttcttcc | ttcttct | 1320 |
| actttgtaa | gacttgtaaa | gatttgctt | gccatacc | gaatcg | tcgaattt | 1380 |
| cgaagctttt | tttatcaaa | aaaaaaaaaa | aaaaaa | | | 1415 |

<210> 58

<211> 374

<212> PRT

<213> Triticum aestivum

<400> 58

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Ile | Pro | Leu | Val | Leu | Val | Leu | Leu | Pro | Leu | Gly | Leu | Leu | Phe |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Leu | Ser | Gly | Leu | Val | Val | Asn | Thr | Val | Gln | Ala | Val | Leu | Phe | Leu |
| | | | | 20 | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ile | Arg | Pro | Phe | Ser | Lys | Arg | Leu | Tyr | Arg | Gln | Ile | Asn | Val | Phe |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ala | Glu | Leu | Leu | Trp | Leu | Gln | Leu | Ile | Trp | Leu | Val | Asp | Trp | Trp |
| | | 50 | | | | 55 | | | | 60 | | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Gly | Ile | Lys | Val | Gln | Val | Tyr | Ala | Asp | Pro | Glu | Thr | Trp | Lys | Leu |
| 65 | | | | 70 | | | | 75 | | | | 80 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Lys | Glu | His | Ala | Leu | Leu | Ile | Ser | Asn | His | Arg | Ser | Asp | Ile |
| | | | | 85 | | | | 90 | | | | 95 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Trp | Leu | Val | Gly | Trp | Ile | Leu | Ala | Gln | Arg | Ser | Gly | Cys | Leu | Gly |
| | | | 100 | | | | 105 | | | | | 110 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ala | Ile | Ala | Ile | Met | Lys | Lys | Ser | Ser | Lys | Phe | Leu | Pro | Val | Ile |
| | | | 115 | | | | 120 | | | | | 125 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Trp | Ser | Met | Trp | Phe | Ala | Glu | Tyr | Leu | Phe | Leu | Glu | Arg | Ser | Trp |
| | | | 130 | | | 135 | | | | 140 | | | | | |

Ala Lys Asp Glu Lys Thr Leu Lys Ser Gly Leu Gln Arg Leu Lys Asp
145 150 155 160

Phe Pro Arg Ser Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg Phe
165 170 175

Thr Pro Ala Lys Leu Leu Ala Ala Gln Glu Tyr Ala Val Ser Gln Gly
180 185 190

Leu Thr Ala Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe Val
195 200 205

Ser Ala Val Ser Ile Met Arg Asp Phe Val Pro Ala Ile Tyr Asp Thr
210 215 220

Thr Val Ile Ile Pro Glu Asp Ser Pro Lys Pro Thr Met Leu Arg Ile
225 230 235 240

Leu Gln Gly Gln Ser Ser Val Val His Val Arg Ile Lys Arg His Ser
245 250 255

Met Ser Asp Met Pro Asn Ser Asp Glu Asp Val Ser Lys Trp Cys Lys
260 265 270

Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Ile Ala Thr
275 280 285

Gly Thr Phe Asp Glu Glu Ile Ile Pro Ile Gly Arg Pro Val Lys Ser
290 295 300

Leu Met Val Val Leu Ser Trp Ser Cys Leu Leu Tyr Gly Ala His
305 310 315 320

Arg Phe Leu Gln Trp Thr Gln Leu Leu Ser Thr Trp Lys Gly Val Ile
325 330 335

Leu Phe Ala Ser Gly Leu Ala Met Val Thr Ala Val Met His Val Phe
340 345 350

Ile Met Phe Ser Gln Ala Glu Arg Ser Ser Ser Ala Lys Ala Ala Arg
355 360 365

Asp Arg Val Lys Lys Asp
370